Washington University in St. Louis

Washington University Open Scholarship
Arts & Sciences Electronic Theses and
Dissertations

Arts & Sciences

Winter 12-15-2021

Regulation of Metabolic Stress by the Snhg3 Locus
Arthur Curtis Sletten
Washington University in St. Louis

Follow this and additional works at: https://openscholarship.wustl.edu/art_sci_etds
Part of the Biology Commons

Recommended Citation
Sletten, Arthur Curtis, "Regulation of Metabolic Stress by the Snhg3 Locus" (2021). Arts & Sciences
Electronic Theses and Dissertations. 2621.
https://openscholarship.wustl.edu/art_sci_etds/2621

This Dissertation is brought to you for free and open access by the Arts & Sciences at Washington University Open
Scholarship. It has been accepted for inclusion in Arts & Sciences Electronic Theses and Dissertations by an
authorized administrator of Washington University Open Scholarship. For more information, please contact
digital@wumail.wustl.edu.

WASHINGTON UNIVERSITY IN ST. LOUIS
Division of Biology and Biomedical Sciences
Molecular Cell Biology

Dissertation Examination Committee
Jean Schaffer, Co-Chair
Brian Finck, Co-Chair
Nicholas Davidson
Daniel Ory
Gary Patti
Joel Schilling

Regulation of Metabolic Stress by the Snhg3 Locus
By
Arthur Sletten

A dissertation presented to
The Graduate School
of Washington University in
partial fulfillment of the
requirements for the degree
of Doctor of Philosophy

May 2022
St. Louis, Missouri

© 2022, Arthur Sletten

Table of Contents
List of Figures .................................................................................................................. v
List of Tables. ..................................................................................................................vii
Acknowledgments .......................................................................................................... viii
Abstract ............................................................................................................................ x
Chapter 1: Introduction to obesity and diabetes
1.1

Obesity is a global epidemic ............................................................................... 1

1.2

Systemic metabolic dysregulation in obesity ...................................................... 2

1.3

Lipotoxicity .......................................................................................................... 5

1.4

Nonalcoholic fatty liver disease ........................................................................... 9

1.5

Small nucleolar RNAs mediate lipotoxicity and metabolic stress ...................... 10

Chapter 2: Snhg3 haploinsufficiency attenuates metabolic stress
2.1

Introduction ....................................................................................................... 15

2.2

Results .............................................................................................................. 17

2.2.1

Snhg3 mutants are resistant to lipotoxic cell death .................................... 17

2.2.2

The SNHG3 lncRNA is dispensable for palmitate-induced cell death ........ 18

2.2.3

Snhg3 mutants are resistant to oxidative stress ......................................... 19

2.3

Conclusions ...................................................................................................... 20

2.4

Figures .............................................................................................................. 21

Chapter 3: Metabolic rewiring in Snhg3 mutant cells
3.1

Introduction ....................................................................................................... 25

3.2

Results .............................................................................................................. 27

3.2.1

Glycolytic flux in Snhg3 mutants ................................................................ 27

3.2.2

Oxidative glucose metabolism is elevated in Snhg3 mutants .................... 28

3.2.3

U17 snoRNA deficiency upregulates fatty acid and glutamine oxidation ... 29

3.2.4

Reduced U17 snoRNA expression blunts mitochondrial oxidative stress .. 29

3.3

Conclusions ...................................................................................................... 30
ii

3.4

Figures .............................................................................................................. 31

Chapter 4: rRNA processing in Snhg3 mutant cells
4.1

Introduction ....................................................................................................... 38

4.2

Results .............................................................................................................. 41

4.2.1

Altered kinetics of rRNA production in 2E4 cells ........................................ 41

4.2.2

mTOR signaling is activated in 2E4 cells ................................................... 41

4.2.3 Oxidative stress resistance and metabolic rewiring in 2E4 cells requires
mTOR activity .......................................................................................................... 42
4.2.4 mTOR inhibition exacerbates rRNA processing defects during U17 snoRNA
deficiency ................................................................................................................. 43
4.2.5 Deletion of Rpl13a snoRNAs does not alter rRNA production or mTOR
signaling .................................................................................................................. 44
4.2.6

Knockdown of U17 snoRNAs in vivo recapitulates 2E4 phenotypes ......... 44

4.3

Conclusions ...................................................................................................... 45

4.4

Figures .............................................................................................................. 47

Chapter 5: U17 snoRNAs regulate lipotoxicity in vivo
5.1

Introduction ....................................................................................................... 58

5.2

Results .............................................................................................................. 60

5.2.1

Knockdown of U17 snoRNAs ameliorates diet-induced lipotoxicity ........... 60

5.2.2

U17 snoRNAs mediate glucose homeostasis during high-fat diet feeding . 61

5.3

Conclusions ...................................................................................................... 63

5.4

Figures .............................................................................................................. 64

Chapter 6: Summary and discussion
6.1

Summary ........................................................................................................... 72

6.2

Lipotoxicity, oxidative stress, and metabolic rewiring ....................................... 73

6.3

rRNA biogenesis and cell metabolism .............................................................. 76

6.4

U17 snoRNAs and metabolic stress in vivo ...................................................... 82

6.5

Future directions and outstanding questions .................................................... 85

iii

Chapter 7: Materials and methods.............................................................................. 89
References .................................................................................................................. 104

iv

List of Figures
Chapter 2
Figure 2.1 Snhg3 mutant cells are protected from lipotoxicity. ...................................... 21
Figure 2.2 SNHG3 lncRNA is dispensable for lipotoxicity. ............................................. 22
Figure 2.3 Snhg3 deficiency protects against oxidative stress. ..................................... 23
Figure 2.4 2E4 mutant cells display altered redox state. ............................................... 24
Chapter 3
Figure 3.1 Reduced extracellular acidification rates in 2E4 cells. .................................. 31
Figure 3.2 Glycolysis metabolites in WT and 2E4 cells. ................................................ 32
Figure 3.3 Glucose oxidation is enhanced in 2E4 cells. ................................................. 33
Figure 3.4 Synthesis of glutathione from glucose is enhanced in 2E4 cells. ................. 34
Figure 3.5 Augmented glutamine and fatty acid oxidation in 2E4 cells. ......................... 35
Figure 3.6 NAD(H) pools and mitochondrial oxidative stress in 2E4 mutants. ............... 36
Figure 3.7 Expression of TCA cycle and b-oxidation enzymes and mitochondrial
abundance in WT and 2E4 cells. ................................................................................... 37
Chapter 4
Figure 4.1 U17 snoRNA haploinsufficiency alters kinetics of rRNA processing. ............ 47
Figure 4.2 Upregulated mTOR signaling in 2E4 cells. ................................................... 48
Figure 4.3 U17 snoRNA knockdown in NSF cells activates mTOR-AKT axis. .............. 49
Figure 4.4 mTOR activity is required for oxidative stress resistance in 2E4 cells. ......... 50
Figure 4.5 Increased glucose oxidation in 2E4 cells is mTOR-dependent. .................... 51
Figure 4.6 mTOR inhibition exacerbates rRNA production defects during U17 snoRNA
deficiency. ...................................................................................................................... 52
Figure 4.7 mTOR signaling and rRNA production are not altered in Rpl13a snoless
primary hepatocytes. ...................................................................................................... 53
Figure 4.8 U17 snoRNA knockdown increases hepatic NADPH. .................................. 54
Figure 4.9 Deficiency of U17 snoRNAs reduces glutathione oxidation in the liver. ....... 55
Figure 4.10 U17 snoRNA knockdown alters rRNA processing in the liver. .................... 56
Figure 4.11 U17 snoRNA knockdown activates hepatic mTOR signaling. .................... 57
v

Chapter 5
Figure 5.1 Snhg3 expression is induced by the MCD diet. ............................................ 64
Figure 5.2 U17 snoRNA knockdown reduces neutrophil infiltration in MCD diet. .......... 65
Figure 5.3 U17 snoRNA knockdown reduces crown-like structures in MCD diet. ......... 66
Figure 5.4 Knockdown of U17 snoRNAs reduces hepatic steatosis and oxidative stress
induced by MCD diet. ..................................................................................................... 67
Figure 5.5 Hepatic fibrosis response after 3 weeks of MCD feeding. ............................ 68
Figure 5.6 mRNA markers of MCD-induced stellate cell activation are reduced by U17
snoRNA knockdown. ...................................................................................................... 69
Figure 5.7 U17 knockdown does not reduce weight gain during high-fat feeding. ......... 70
Figure 5.8 U17 snoRNA depletion regulates glucose homeostasis during high-fat
feeding. .......................................................................................................................... 71

vi

List of Tables
Chapter 7
Table 1: Oligonucleotide sequences . .......................................................................... 100

vii

Acknowledgements
First and foremost, I thank my thesis advisor, Dr. Jean Schaffer. Her mentorship has
helped me grow tremendously as a scientist during my time in her laboratory. She has
challenged me to think critically about all aspects of my project and to develop and pursue
new ideas. Her optimism and constant support have been sources of inspiration for me,
especially during challenging experiments and setbacks. Her incredible attention to detail,
and the countless hours she has spent editing my manuscripts and presentations, have
taught me to communicate science more effectively. These are skills I will use throughout
my career and I am incredibly grateful for the time and effort she has invested in my
scientific development. I would also like to thank Dr. Daniel Ory, who has provided me
with mentorship and guidance since I was an undergraduate in the Amgen Scholars
Program. This experience was the primary reason I joined the MSTP at Washington
University.

I would like to thank my thesis committee – Dr. Brian Finck, Dr. Nicholas Davidson, Dr.
Joel Schilling, and Dr. Gary Patti – for their support over the last three years. You have
helped me think about experiments outside my comfort zone and to extend my work to
new contexts. Each one of you has contributed generously, directly, and significantly
toward advancing my project. Thank you.

To the members of the Schaffer and Ory labs, both past and present, thank you for your
friendship and support over the last four years. I would not have made it through this
process without you. To Josh Langmade, Sarah Gale, Jamie Rimer, Jessie Zhang, Lexi
viii

Harris, and Glendoria Elliot – the advice and assistance you have given me has been
instrumental for my success and it was such a pleasure to work with you. I would like to
extend a special thanks to Samantha Moores and Jessica Davidson for their tremendous
help with my animal experiments at the Schaffer lab in Boston. Hideji Fujiwara, Xuntian
Jiang, and Rohini Sidhu at the Washington University Metabolomics Facility have been
critical for LC-MS/MS experiments and analysis. I would also like to thank my friends and
fellow graduate students, Melissa Li and McKenna Feltes, for being truly wonderful
companions during our time in lab together, and David Scherrer, for his profound
philosophical musings and guidance.

Finally, I would like to thank my family. To my wife, Sonya – thank you for being with me
through the ups and downs of graduate school. Your encouragement has helped me stay
motivated even though I have not always been confident in myself. To my parents – thank
you for your constant support, your generosity, and the sacrifices you have made to
ensure I have had every opportunity to succeed.

Arthur Sletten
Washington University in St. Louis
May 2022

ix

ABSTRACT OF DISSERTATION
Regulation of Metabolic Stress by the Snhg3 Locus
By
Arthur Sletten
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2022
Professor Jean Schaffer, Co-Chairperson
Professor Brian Finck, Co-Chairperson
Dyslipidemia and lipotoxicity are pathologic signatures of the metabolic syndrome and
type 2 diabetes. Excess lipid causes cell dysfunction and induces cell death through
pleiotropic mechanisms that link to oxidative stress. However, pathways that regulate the
response to metabolic stress are not fully understood. To identify novel genes involved in
metabolic stress, our group performed an unbiased forward genetic screen for lipotoxicity
resistance. My studies focused on characterizing one of the mutant cell lines isolated from
this screen, in which promoter trap mutagenesis disrupted one allele of the small
nucleolar RNA hosting gene 3 (Snhg3).

I demonstrate that diminished expression of U17 snoRNAs from Snhg3 causes resistance
to lipid-induced cell death and general oxidative stress in cultured cells. Protection from
metabolic stress in U17 snoRNA-deficient cells is associated with broad reprogramming
x

of oxidative metabolism, characterized by increased catabolism of glucose, fatty acids,
and amino acids. This metabolic rewiring contributes to increased antioxidant capacity
and altered redox balance, and is dependent on upregulated signaling through the
mammalian target of rapamycin (mTOR) axis, a consequence of alterations in U17
snoRNA-mediated rRNA processing.

I extended my analyses by showing that knockdown of U17 snoRNAs in the liver
recapitulates many phenotypic aspects of Snhg3 mutant cells, including increased
antioxidant capacity, altered rRNA processing, and augmented mTOR signaling. Using
the methionine- and choline-deficient diet (MCD) murine model of hepatic lipotoxicity, I
show that depletion of U17 snoRNAs suppresses hepatic steatosis, oxidative stress, and
inflammatory cell infiltration. Hepatic stellate cell activation, as measured by expression
of pro-fibrotic mRNA transcripts, was also blunted by U17 snoRNA knockdown. To
examine the role of U17 snoRNAs in the metabolic syndrome, I used high-fat diet (HFD)
feeding to induce obesity and insulin resistance in C57BL6/J mice. In this model, U17
snoRNA depletion improved glucose tolerance and insulin-mediated glucose disposal
without affecting weight gain. These findings suggest that genetic changes resulting in
decreased expression or function of U17 snoRNAs could contribute to phenotypic
variability in diet-induced metabolic dysfunction including fatty liver disease and insulin
resistance.

xi

Chapter 1:
Introduction
1.1 Obesity is a global epidemic
Over the past four decades there has been a dramatic rise in the global prevalence of
obesity. Advancing urbanization, sedentary lifestyles, excessive caloric intake, and lack
of supportive health policies have doubled the number of obese individuals worldwide
since 1980.1,2 In 1980, less than 8% of the global adult population aged 18 years or older
was obese (body mass index (BMI) >30 kg/m2), and less than 1% of children were obese.
In 2016, 40% of adults were overweight (body mass index >25 kg/m2) and 13% classified
as obese (BMI >30 kg/m2).1,3 During this same time period, the prevalence of obesity has
increased five-fold in children. Once considered a burden exclusively in wealthy nations,
obesity increasingly plagues low- and middle-income countries, including those in Africa
and Asia. Excepting parts of sub-Saharan Africa, more people are obese than
underweight.2

Obesity is associated with numerous diseases that contribute to morbidity and mortality.
Obese individuals have a markedly increased incidence of cardiovascular risk factors,
including hypertension, hyperlipidemia, and type 2 diabetes. These factors dramatically
elevate the risk of coronary artery disease, heart failure, and stroke, together accounting
for more than 50% of deaths in obese and diabetic individuals.3,4 Microvascular
complications associated with diabetes, including retinopathy, neuropathy, and kidney
failure, increase disease burden in obese individuals.1 The incidence of numerous
1

cancers (endometrial, breast, prostate, colon, and kidney) are strongly correlated with
elevated

BMI.5

Obesity-associated

musculoskeletal

degeneration,

particularly

osteoarthritis, is a leading cause of disability, wage losses, and financial losses due to
reduced productivity.6

Obesity and its sequelae are leading causes of mortality worldwide. More than 5% of all
deaths are attributable to obesity.2 In 2016, diabetes alone directly caused 1.5 million
deaths and was the seventh leading cause of death overall.2 Moreover, obesity is a major
threat to the global economy. Worldwide, the economic impact of obesity was estimated
to be more than 2 trillion dollars or nearly 3% of the global gross domestic product.7 In
the United States, obesity-related health care expenditure accounted for more than 342
billion dollars in 2013, equal to more than 28% of annual medical spending.8 As the
incidence of obesity continues to rise, the human and financial costs will become more
severe. In addition to preventative strategies, including supportive health policies and
greater access to primary medical care, a more rigorous basic understanding of obesity
– its genetic contributions, pathogenesis, and connections to associated diseases – is
essential to address this global health crisis.

1.2 Systemic metabolic dysregulation in obesity
Altered glucose homeostasis, manifested by hyperglycemia and glucose intolerance, is a
hallmark of obesity. Nearly two-thirds of obese individuals have type 2 diabetes, although
a small proportion of obese patients are metabolically “healthy” and remain insulin
sensitive.9 As opposed to type 1 diabetes, a result of autoimmune destruction of
pancreatic b-cells and failure to produce insulin, hyperglycemia in type 2 diabetes is
2

caused primarily by failure of tissues to take up glucose in response to insulin, a
phenomenon known as insulin resistance.10 Regardless of cause, chronic hyperglycemia
per se promotes macro- and microvascular complications of both type 1 and type 2
diabetes.11 In response to excessive sugar exposure, proteins and lipids within blood
vessels and tissues are glycosylated non-enzymatically to form advanced glycation end
products (AGEs). AGEs induce inflammation, oxidative stress, and cell death within
tissues and endothelial surfaces, contributing to development of atherosclerosis,
neuropathy, retinopathy, and glomerulopathy.11,12 Interestingly, tight glycemic control in
type 2 diabetes reduces incidence of microvascular disease (e.g., retinopathy) but not
macrovascular disease (e.g., coronary artery disease), highlighting the importance of
other metabolic disturbances in diabetes.13,14

In healthy individuals, insulin is released into circulation by pancreatic b-cells in response
to postprandial elevations in blood glucose and stimulates glucose uptake in skeletal
muscle and adipose tissue. Patients with type 2 diabetes, in which insulin signaling in
these metabolic tissues is dampened, require more insulin secretion to deliver glucose
for

energy

consumption

and

to

maintain

euglycemia.

This

compensatory

hyperinsulinemia occurs early in the natural history of type 2 diabetes and initially helps
to achieve normal glucose tolerance. However, as insulin resistance in peripheral tissues
progresses, hyperinsulinemia no longer provides adequate compensation in glucose
disposal, and hyperglycemia develops. The onset of hepatic insulin resistance,
characterized by the failure of insulin to suppress gluconeogenesis, further exacerbates
hyperglycemia.

3

Hyperinsulinemia is also critical factor in the pathogenesis of many diabetic
complications. Persistent demand for insulin synthesis, coupled with hyperglycemia,
causes endoplasmic reticulum (ER) and oxidative stress in b-cells and contributes to their
dysfunction and failure late in the course of diabetes. Chronic elevations in insulin drive
hepatic lipogenesis and very low-density lipoprotein (VLDL) production, causing
hyperlipidemia and hepatic steatosis. Excessive insulin signaling promotes adipose
tissue macrophage infiltration and inflammation.15 In skeletal muscle arterioles,
hyperinsulinemia induces endothelin expression and reduces NO production, leading to
endothelial dysfunction and impaired vasodilation.16 In the heart, high levels of insulin
promote atherosclerosis and correlate strongly with onset of coronary artery disease.17
As insulin is a potent mitogen, prolonged hyperinsulinemia is associated with numerous
cancers.18

Aberrant lipid metabolism is another cardinal feature of obesity and diabetes.
Dyslipidemia in obesity is characterized by elevated fasting triglycerides (TG) and free
fatty acids (FFAs) in combination with high low-density lipoprotein (LDL) and low highdensity lipoprotein (HDL) cholesterol.19 Diverse mechanisms involving lipoprotein
metabolism and cellular fatty acid metabolism underlie this dyslipidemia. Obesity-driven
transcriptional changes elevate circulating triglycerides and LDL through reduced
expression of lipoprotein lipase and the LDL receptor as well as through upregulation of
genes involved in de novo lipogenesis.20 Accumulation of TG-rich lipoproteins depletes
HDL via augmented transfer of cholesteryl esters by CETP.21 At the cellular level, chronic
nutrient overload leads to oxidative stress and mitochondrial damage that impairs TG
uptake and fatty acid b-oxidation.22,23
4

Elevated circulating FFA may be the most consequential feature of obesity-induced
dyslipidemia. Plasma FFAs are increased in obesity as a result of enlarged adipose
depots, reduced FFA uptake by metabolic tissues, and impaired insulin-mediated
suppression of adipose lipolysis.24 Many studies have shown that FFA acids mediate
many of the metabolic disturbances observed in obesity. Acutely raising FFA through
infusion of lipid emulsions reduces insulin-stimulated glucose uptake dose-dependently
in individuals regardless of BMI, age or sex.25 Conversely, reversing elevated FFA in
obese subjects normalizes insulin-stimulated glucose uptake.26 In the liver, insulin
suppresses

hepatic

glucose

production

by

inhibition

of

glycogenolysis

and

gluconeogenesis. Physiologic elevations in plasma FFA, such as those occurring after a
fat-rich meal, blunt insulin-mediated suppression of hepatic glucose production to
promote hyperglycemia.27 Obesity is also associated with elevated levels of proinflammatory cytokines, including TNF-a, IL-1, and IL-6, that promote tissue and
endothelial inflammation.24 Acute administration of FFAs induces hepatic expression of
these cytokines, providing strong link between high-fat feeding and systemic inflammatory
changes.28 Finally, FFAs exacerbate endothelial inflammation by dampening insulinmediated endothelial nitric oxide production.29,30

1.3 Lipotoxicity
During obesity and diabetes, adipose depots expand dramatically to store excess lipids
as TGs within lipid droplets. However, the capacity of adipose tissue to store TGs is finite,
and during obesity and diabetes this limit is surpassed. As a result, TGs and FFAs are
deposited in many non-adipose tissues including the liver, skeletal muscle, and heart.31
5

While these tissues can metabolize FFAs and store them as TGs to a limited extent, these
processes are quickly overwhelmed and toxic lipids and their metabolites accumulate,
causing cell death and tissue dysfunction through a process termed lipotoxicity.32,33

Numerous studies in cultured cells and animal models have provided insights into the
molecular mechanisms of lipotoxicity. Lipid overload is associated with generation of
reactive oxygen species (ROS) in multiple cellular compartments.34 In many cell types,
excessive delivery of FFAs and TGs augments b-oxidation, leading to elevated
mitochondrial substrate metabolism and production of reactive oxygen species (ROS) via
the electron transport chain.35 Lipotoxic conditions also activate nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase to promote production of cytosolic superoxide.
Lipid-induced activation of NADPH oxidase may occur directly, via binding of lipid
metabolites including diacylglycerol and phosphatidic acid, or through protein kinase C
signaling in certain cell types.36,37

A key consequence of this excess ROS is lipid peroxidation. Accumulation of highly
reactive peroxidized lipid species during lipotoxicity, including 4-hydroxy nonenal, 4hydroxy hexenal, and oxidized cardiolipin, enhances ROS propagation, damages cellular
membranes, and impairs organelle function.38 Compromised mitochondrial membranes
release cytochrome c and aggravate pro-apoptotic pathways.39 The importance of
oxidative stress in the pathogenesis of lipotoxicity is underscored by findings that
administration of antioxidants ameliorate lipid-induced cell death.40,41

6

As the primary site of sterol and phospholipid metabolism, the ER is a central hub of lipid
homeostasis. Many proteins that govern lipid metabolism also localize to ER membranes.
Lipid overload, in vitro and in vivo, causes marked induction of ER stress as evidenced
by increased expression of chaperone GRP78, X-box binding protein-1 (XBP1), and
phosphorylation of eIF2 and PERK.42 Reducing ER stress with chemical chaperones or
deletion of XBP1 ameliorates insulin resistance and restores glucose control in db/db
mice.43 Diversion of excess lipid away from ER membranes through augmented fatty acid
metabolism or sequestration within TGs also reduces ER stress and lipotoxicity,
highlighting a key role for ER stress in the pathogenesis of lipotoxicity.44 There are likely
several mechanisms through which FFAs promote ER stress. During exposure to high
concentrations of saturated fatty acids, these excess lipids incorporate into membrane
phospholipid pools. In the ER, membrane remodeling can impair membrane integrity,
diminish activity of resident enzymes, and alter protein trafficking. ROS generated during
lipotoxicity oxidize ER membranes and proteins, trigger calcium efflux, and stimulate
caspase-mediated cell death.45

Ceramides are sphingolipids that make up cell membranes in many tissues and drive
signaling pathways during cell stress and apoptosis initiation.46 During lipotoxicity,
ceramide levels increase dramatically, as the saturated fatty acids palmitate and stearate
are precursors for de novo ceramide biosynthesis.47 Ceramides contribute directly to
insulin resistance through inhibition of insulin signaling and disruption of mitochondrial
metabolism.48 However, whether ceramides are required for lipotoxic cell death appears
to be tissue- and cell type-specific. In skeletal myocytes, endothelial cells, and pancreatic
b-cells, administration of ceramide synthesis inhibitors abrogates cell death.49,50 In murine
7

models of cardiac lipid overload, ceramide synthesis reduces hypertrophy and improves
cardiac function.51,52 By contrast, blockade of de novo ceramide synthesis does not
ameliorate lipotoxicity in hepatocytes and fibroblasts.41,53 These findings underscore the
diverse pathways for lipid-induced injury in various tissues.

Obesity and diabetes are associated with chronic low-grade inflammation in many
tissues, referred to as metainflammation to reflect the metabolic nature of its
pathogenesis.34 Pleotropic mechanisms underlie lipid-induced inflammation. ER stress,
induced by saturated fatty acid and cholesterol loading, converges with inflammatory
responses via activation of several stress response kinases, including JNK, PKR, and
IKK.34 These pathways engage the downstream transcription factor activator protein 1
(AP-1) to increase transcription of TNF-a, IL-1b, and other pro-inflammatory
cytokines.54,55

Increased

ROS

production

during

lipotoxicity

activates

the

inflammasome.56 Saturated fatty acids also promote inflammation through direct actions
on enzymes and intracellular signaling cascades. Excess palmitate augments synthesis
of diacylglycerols (DAGs), which can stimulate specific protein kinase C (PKC) isoforms
including PKC-e and PKC-q.57 These PKC enzymes trigger activation of NF-kB to promote
synthesis of pro-inflammatory cytokines and also dampen insulin signaling through
inhibiting tyrosine phosphorylation of the insulin receptor substrate 1 (IRS-1) and its
downstream effector AKT.58,59 DAG-mediated activation of PKCs has been proposed as
the primary driver of insulin resistance in skeletal muscle and the liver. Palmitate can also
increase NF-kB-mediated inflammation through activation of toll-like receptor 4 (TLR4) in
certain cell types.60 As a result, circulating inflammatory cytokines are increased in
obesity, and these cytokines then aggravate stress responses in other tissues.
8

1.4 Nonalcoholic fatty liver disease
Nonalcoholic fatty liver disease (NAFLD) affects 20% of US adults and is one of the most
common conditions associated with diabetes and obesity.61 NAFLD encompasses a
broad spectrum of pathologies associated with lipid accumulation and is the principal
manifestation of lipotoxicity in the liver.62 The natural history of NAFLD involves three
progressive phases.63 In its earliest stage, NAFLD is characterized by simple
macrovesicular hepatic steatosis without cytotoxicity. In approximately 20% of NALFD
patients, steatosis progresses to nonalcoholic steatohepatitis (NASH), a condition
characterized by neutrophilic inflammation, fibrosis, and hepatocellular death. This
inflammatory evolution features many stigmata of lipotoxicity, including ER stress,
mitochondrial dysfunction, and oxidative damage.62 Though reversible, NASH can
progress to cirrhosis and is the second most common underlying disorder that leads to
liver transplantation in United States after alcoholic liver disease.64 NASH is also a
significant risk factor for hepatocellular carcinoma. Currently, there are no FDA-approved
pharmacologic therapies for NAFLD, and treatment focuses primarily on lifestyle
modification including diet, weight loss, and exercise.65 Given its strong association with
the metabolic syndrome, the burden of NAFLD on healthcare systems worldwide are
expected to rise dramatically in the next decade along with the incidence of obesity and
diabetes.65

A critical gap in our understanding of NAFLD pathogenesis is the mechanism that links
lipid accumulation to hepatocellular death and inflammation, as less than a fifth of patients
with hepatic steatosis develop NASH. It is hypothesized that a “second hit” during lipid
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overload drives the progression to steatohepatitis, although a consensus regarding the
identify of this stimulus has not been reached. Pharmacologic and dietary agents that
reduce oxidative stress, increase hepatic lipid oxidation, and improve insulin sensitivity
have been shown to reduce steatosis and steatohepatitis in several murine models of
NASH.66 In clinical trials, pioglitazone and vitamin E improve aspects of NASH pathology,
but the long-term health effects of these interventions require further study.67-69 Numerous
studies have highlighted activation of hepatic stellate cells as the critical driver of
steatohepatitis, as their ablation or manipulation of glucose metabolism reduces
inflammation and fibrosis in dietary models of NASH.70-72 The mechanism through which
lipid overload in hepatocytes triggers stellate cell activation is not completely understood.
Studies that investigate the basic mechanisms that govern hepatic lipid accumulation and
its transition to lipotoxicity will be highly beneficial for informing future NASH therapies.

1.5 Small nucleolar RNAs mediate lipotoxicity and metabolic stress
The cellular mechanisms that contribute to lipid-induced cell death are complex and often
tissue- or cell type-specific. However, a key feature of lipotoxicity in vivo is accumulation
of lipid in non-adipose tissues with subsequent metabolic stress and cell death. To gain
a mechanistic understanding of these processes, the Schaffer laboratory developed
models of in vitro lipotoxicity in which cultured cells are grown in medium supplemented
with pathophysiological levels of long chain fatty acids.32,41 In this system, cells exhibit
steatosis in response to unsaturated fatty acids and demonstrate ER stress, ROS, and
cell death in response to saturated fatty acids.41
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The Schaffer group leveraged this model to perform a promoter trap mutagenesis screen
in Chinese hamster ovary (CHO) cells to uncover novel genes that regulate lipotoxicity
and metabolic stress. In this approach, CHO cells were mutagenized by transduction with
the ROSAbgeo retrovirus to achieve less than 1 integration per cell.73 The integrated
provirus encodes a promoter-less b-galactosidase-neomycin phosphotransferase fusion
cassette with strong polyadenylation sequences, such that its transcription only occurs if
the integration site is downstream of an active RNA polymerase II promoter. Transcription
produces a polyadenylated fusion transcript comprised of sequences from the
endogenous gene upstream of the splice donor and sequences from ROSAbgeo
downstream of the splice acceptor, including strong polyadenylation sequences. This
results in a transcript that encodes neomycin phosphotransferase and disruption of
expression of the gene at the site of integration. Following neomycin selection, the stably
transduced population was subjected to growth in lipotoxic concentrations of palmitic acid
and resistant mutants were isolated. Once mutants were isolated, the site of proviral
integration was identified by rapid amplification of 3’ cDNA ends (RACE).

This genetic screen identified several loci that are required for lipotoxicity, many in
pathways previously not associated with lipid metabolism or metabolic stress.74-77 One of
the first genes to be identified with this technique is the ribosomal protein L13a (Rpl13a)
locus.77 This gene is comprised of eight exons that encode the Rpl13a protein, a
component of the large ribosomal subunit. Within the intronic sequences are four box C/D
small nucleolar RNAs (snoRNAs) – U32a, U33, U34, and U35a – that are excised from
intron lariats during splicing of the Rpl13a pre-mRNA. Surprisingly, complementation and
directed knockdown experiments demonstrated that Rpl13a snoRNAs, not the Rpl13a
11

protein, were required for lipid-induced oxidative stress and cell death. Deficiency of
Rpl13a snoRNAs also protected cultured cells from general oxidative stress and their
knockdown in vivo protected hepatocytes from LPS-induced oxidative damage. These
studies were the first to implicate snoRNAs in lipotoxicity and contributed to a much
broader appreciation for this class of noncoding RNAs as mediators of metabolic stress.
Other mutants isolated in this screen further demonstrate the importance of snoRNAs in
metabolic stress. For example, disruption of the Smd1 locus, a core component of the
spliceosome that is necessary for liberation of snoRNAs from intron lariats, protects cells
from lipotoxicity.78 In another example, mutants with reduced expression of small
nucleolar RNA hosting gene 3 (Snhg3), which encodes the intronic box H/ACA U17
snoRNAs, are similarly resistant to lipid-induced cell death. The mechanisms through
which snoRNAs mediate lipotoxicity and metabolic stress are not fully understood.

snoRNAs are short noncoding RNAs ranging between 60-250 nucleotides in length and
are categorized within two major classes, box C/D and box H/ACA, based on highly
conserved sequence motifs.79 In vertebrates, most snoRNAs are found within intronic
sequences and are processed from intron lariats during splicing. However, some
snoRNAs, including U3, U8, and U13, are independently transcribed by RNA polymerase
II.80 Once transcribed, snoRNAs associate with numerous proteins to form small nucleolar
ribonucleoproteins (snoRNPs) and localize primarily within nucleoli where they direct
covalent modifications of other noncoding RNAs. Box C/D snoRNPs contain the
methyltransferase fibrillarin and mediate 2’-O-methylation of ribosomal RNAs (rRNAs),
while box H/ACA snoRNAs associate with dyskerin, a pseudouridine synthase, and guide
pseudouridylation of rRNAs and transfer RNAs (tRNAs).79 Both classes of snoRNAs
12

contain short antisense elements (10-20 nucleotides) that are complementary to
sequences on target RNAs.81 Through these interactions, snoRNPs are guided to precise
modification sites. In some cases, snoRNA-mediated nucleotide modifications are
required for stability of rRNA and tRNA secondary structures and proper ribosome and
spliceosome function.82 Certain snoRNAs, such as the U17 snoRNAs, mediate
nucleolytic cleavage of pre-rRNA transcripts and participate directly in rRNA biogenesis.83
Emerging evidence also suggests that snoRNAs may participate in functions beyond
rRNA and tRNA modification, including roles in pre-mRNA splicing, RNA editing, miRNAlike post-transcriptional regulation, and pseudouridylation of mRNAs.84-86

A growing body of literature implicates snoRNAs in disease pathogenesis. Alterations in
expression of many snoRNAs are associated with tumorigenesis: more than 46 snoRNAs
are upregulated in cancers and correlate with disease progression and prognosis.87
Snord50 functions as a tumor suppressor through inhibition of K-RAS to regulate
proliferation in breast and prostate cancers.88 For the majority of snoRNAs implicated in
cancer, however, a mechanistic understanding of their function is lacking. Upregulation
of snoRNA expression in cancer may reflect increased protein synthesis in rapidly
growing cells, but the upregulated expression of only a select few snoRNAs suggests a
more complicated interpretation.

snoRNAs have also been implicated in regulation of metabolism and metabolic stress.
Mice lacking the Rpl13a snoRNAs have reduced ROS tone in pancreatic islets, exhibit
improved glucose tolerance, and are protected from streptozotocin-induced diabetes.89
In response to lipid-induced oxidative stress, multiple snoRNAs associate with PKR
13

kinase to regulate protein synthesis and inflammatory responses.90 U17 snoRNAs
regulate cholesterol trafficking and steroidogenesis.91 Snord116 regulates the function of
hypothalamic NPY neurons to control food intake and energy expenditure, and deletion
of this snoRNA in Prader-Willi syndrome contributes to profound hyperphagia and weight
gain.92

The discovery that snoRNAs respond to and mediate changes in cellular metabolism has
provided unexpected and exciting insight into the basic mechanisms of lipotoxicity and
metabolic stress. The studies presented in this dissertation provide further evidence of
this phenomenon and broaden our understanding of how snoRNAs regulate cell
metabolism. Using the aforementioned genetic screen for lipotoxicity resistance, our
group has identified the intronic box H/ACA U17 snoRNAs encoded within the Snhg3
locus as novel regulators of lipotoxicity. To furnish a mechanism for this process, I
examine the role of U17 snoRNAs in oxidative metabolism, rRNA biogenesis, and cellular
redox balance. These findings are extended to murine models of NAFLD and obesity to
gain insight into the role of U17 snoRNAs in steatohepatitis and the metabolic syndrome.
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Chapter 2:
Snhg3 deficiency reduces metabolic stress
2.1 INTRODUCTION
The cellular response to lipid overload involves simultaneous activation of multiple stress
signaling pathways before culminating in cell death. The intricate connections between
these pathways – including ER stress, oxidative stress, autophagy, and mitochondrial
metabolism – are only beginning to be understood. Given the central role of lipotoxicity in
the pathogenesis of obesity and diabetes, a thorough dissection of the basic mechanisms
of lipid overload is needed to make further strides in therapeutic approaches toward these
metabolic diseases.

To uncover novel genes involved in lipotoxicity and metabolic stress, the Schaffer lab
performed a promoter trap mutagenesis screen in CHO cells. In this approach, cells were
mutagenized by transduction with the ROSAbgeo retrovirus, which encodes a promoterless b-galactosidase-neomycin phosphotransferase fusion cassette with strong
polyadenylation sequences. Therefore, its transcription only occurs if the integration site
is downstream of an active RNA polymerase II promoter. Transcription produces a
polyadenylated fusion transcript comprised of sequences from the endogenous gene
upstream of the splice donor and sequences from ROSAbgeo downstream of the splice
acceptor. This results in a transcript that encodes neomycin phosphotransferase and that
disrupts expression of the gene at the site of integration. After neomycin selection, the
stably transduced population was subjected to lipotoxic concentrations of palmitic acid to
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isolate resistant mutants. To identify the disrupted gene within these mutant cells, the site
of proviral integration was identified by rapid amplification of 3’ cDNA ends (RACE).

This approach identified several loci that are required for cell death in response to lipid
overload.74,75,77 Interestingly, cell lines harboring mutations in the small nucleolar RNA
hosting gene 3 (Snhg3) were isolated through this screen. This locus encodes a long
noncoding RNA (lncRNA), SNHG3, and the box H/ACA U17A and U17B snoRNAs. The
U17 snoRNAs are encoded within introns and are liberated upon splicing of the exon
elements during production of the mature SNHG3 lncRNA.93 U17B shares 94% sequence
identity with U17A and likely arose through duplication.93 The SNHG3 lncRNA is
ubiquitously expressed in murine and human tissues.94 Since the SNHG3 lncRNA and
snoRNAs are processed from the same pre-RNA, U17 snoRNAs are also likely to be
widely expressed in human and mouse tissues.

Functional characterization of Snhg3-encoded RNAs is incomplete. SNHG3 lncRNA is
upregulated in hepatocellular and colorectal carcinoma and may serve as an endogenous
competing target for micro-RNAs.95,96 U17A/B snoRNAs are highly conserved
evolutionarily and mediate nucleolytic processing of pre-rRNA during 18S rRNA
production.83,97 Yet they also function in roles beyond rRNA processing. Snhg3 mutant I5
cells, generated by our group through an independent genetic screen, have U17 snoRNAdependent alterations in cholesterol trafficking without changes in 18S rRNA
abundance.91 For this phenotype, U17A and U17B snoRNAs were found to be functionally
redundant. While our genetic screen indicates that Snhg3 is required for lipotoxic cell
death, the relative contributions of the U17A/B snoRNAs and/or the SNHG3 lncRNA to
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this phenotype have not been defined and the molecular mechanisms through which
Snhg3 RNAs function in these processes are unknown.

2.2 RESULTS
2.2.1 Snhg3 mutants are resistant to lipotoxic cell death.
To identify genes involved in lipid-induced cell death, we performed a loss-of-function
screen in CHO cells. Cells were mutagenized by transduction with the ROSAbgeo
retroviral promoter trap to achieve, on average, < 1 integration per cell. Mutants were
screened for the ability to grow in standard culture medium supplemented with 500 µM
palmitic acid. Under these conditions, mutant 2E4 cells, but not wild type (WT) CHO cells,
survived. To assess the specificity of resistance to established inducers of cell death, we
quantified cell death following treatment of 2E4 cells with palmitate, actinomycin D, or
staurosporine. As expected, 2E4 cells were protected from palmitate-induced cell death
compared to WT cells; however, sensitivity to staurosporine and actinomycin D was
similar to WT cells, indicating that general apoptosis is intact in 2E4 mutants (Figure
2.1A).

3’ RACE performed in 2E4 cells indicated that the ROSAbgeo provirus integrated within
the small nucleolar RNA hosting gene 3 (Snhg3) locus, which encodes the SNHG3
lncRNA and the U17 snoRNAs (Figure 2.1B). The expression of SNHG3 lncRNA and
U17 snoRNAs was reduced by 50% in 2E4 cells, indicating that 2E4 mutants exhibit
Snhg3 haploinsufficiency and that its full expression is required for lipotoxicity (Figure
2.1C). This genetic perturbation is similar to another mutant cell line, I5, generated by our
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group in an independent genetic screen for resistance to amphotericin following treatment
with exogenous low-density lipoproteins.91 As with 2E4 cells, I5 mutants are resistant to
lipid-induced cytotoxicity (Figure 2.1A). Mutant 2E4 and I5 cells also generated less ROS
than WT cells in response to lipotoxic concentrations of palmitate (Figure 2.1D). Snhg3
mutants are thus resistant to both lipid-induced oxidative stress and lipid-induced cell
death.

2.2.2 The SNHG3 lncRNA is dispensable for palmitate-induced cell death.

Our prior studies have shown that both lncRNAs and snoRNAs can have critical roles in
lipotoxicity.75,77 To determine whether the lncRNA is the element from this locus that is
required for lipotoxicity, we selectively depleted SNHG3 lncRNA in WT CHO cells and
measured cell death in response to palmitate. We transduced WT cells with short hairpin
constructs targeting SNHG3 lncRNA (shSNHG3) or a scrambled sequence (shSCR).
Relative to shSCR cell lines, shSNHG3 cells showed 50% SNHG3 knockdown, similar to
its expression in 2E4 cells, without altering abundance of the U17A/B snoRNAs (Figure
2.2A). Upon treatment with lipotoxic concentrations of palmitate, shSNHG3 and shSCR
cell lines displayed a similar degree of cell death (Figure 2.2B). These findings
demonstrate that knockdown of the SNHG3 lncRNA alone is not sufficient for protection
from lipotoxic cell death.

Although shRNAs are highly effective for silencing RNAs in the cytoplasm, such as the
SNHG3 lncRNA, an alternate approach was required to knockdown snoRNAs, which
reside primarily in the nucleolus. We designed locked nucleic acid (LNA) oligomers
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complementary to the 3¢ hairpin of U17 snoRNAs, a region that is accessible to nucleases
in box H/ACA snoRNA ribonucleoproteins.98 As controls, we designed a non-targeting
LNA against GFP and an LNA to selectively deplete SNHG3 lncRNA by tiling across the
exon 1-exon 2 splice junction of the mature SNHG3 lncRNA. Transfection of WT NIH 3T3
fibroblasts with U17 LNAs resulted in 50% knockdown of the U17 snoRNAs as well as
knockdown of the SNHG3 lncRNA relative to the control GFP LNA, comparable to
expression of these transcripts in the 2E4 mutant (Figure 2.2C). This suggests that the
U17 LNA can target both the mature snoRNA and the Snhg3 pre-RNA. However,
transfection with the LNA targeting the splice junction of SNHG3 caused 75% knockdown
of the lncRNA without affecting expression of the U17 snoRNAs. Importantly, only
transfection of NIH 3T3 cells with the U17 LNA, but not the SNHG3 LNA, protected cells
from palmitate-induced cell death (Figure 2.2D). We also demonstrated that U17 snoRNA
knockdown in human normal skin fibroblasts (NSF) reduces lipid-induced cytotoxicity
(Figure 2.2E, F). Together, these results in fibroblast lines from three different species
support the hypothesis that the U17 snoRNAs are the elements of the Snhg3 locus
required for lipotoxicity.

2.2.3 Snhg3 mutants are resistant to oxidative stress.

Our finding that Snhg3 mutants show reduced levels of palmitate-induced ROS raised the
possibility that these cells are more broadly resistant to oxidative stress. Indeed, 2E4 cells
treated with hydrogen peroxide show reduced cell death and ROS amplification relative
to WT cells (Figure 2.3A, B). U17 snoRNA knockdown in NSF cells similarly reduced
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H2O2-induced cell death (Figure 2.3C, D). These results suggest that the Snhg3 locus
may regulate lipotoxicity through oxidative stress pathways.

Glutathione (GSH), a critical antioxidant for cell survival during oxidative stress,99 is
regenerated from its oxidized form, glutathione disulfide (GSSG), by glutathione
reductases in a reaction that requires NADPH. To gauge cellular antioxidant capacity, we
quantified the abundance of GSH and NADPH pools. 2E4 cells show higher GSH and a
lower ratio of oxidized to reduced GSH compared to WT cells (Figure 2.4A-C). They also
have higher NADPH levels and a lower ratio of oxidized to reduced NADP(H) (Figure
2.4D-F). These data suggest that reduced expression of the Snhg3 locus leads to
protection from oxidative stress by modulating the cellular redox environment.

2.3 CONCLUSIONS
Through an unbiased forward genetic screen for palmitate resistance, our group identified
Snhg3 as a novel gene that is required for lipid-induced oxidative stress and cell death.
Directed knockdown experiments demonstrated that the highly conserved U17 snoRNAs
expressed by this locus are the RNA elements that mediate the cellular response to lipid
overload. Snhg3 mutant cells are also resistant to general oxidative stress induced by
hydrogen peroxide and have an augmented GSH/NADPH antioxidant system. These data
support the finding that administration of antioxidants can mitigate lipid-induced cell death
and underscore the importance of oxidative stress pathways in lipotoxicity.75,100 Together,
our results indicate that U17 snoRNAs regulate cellular redox tone to guide responses to
lipotoxic and metabolic stress.
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Figure 2.1 Snhg3 mutant cells are protected from lipotoxicity.
A. Cell death in CHO wild type (WT) and mutant I5 and 2E4 cells treated for 48 h with
500 µM palmitate complexed to bovine serum albumin (BSA) (PALM) or BSA carrier
alone (BSA), or treated for 24 h with 2 µM actinomycin D (ACT), 80 nM staurosporine
(STR), or DMSO vehicle. Cell death determined by propidium iodide and annexin V-GFP
staining with flow cytometric analysis of 104 cells/sample.
B. Snhg3 locus, showing exons as grey rectangles and snoRNAs as black ovals. Arrows
indicate sites of ROSAbgeo (ROSA) proviral integration in mutant 2E4 and I5 cells.
C. Expression of SNHG3 lncRNA and U17 snoRNAs relative to Rplp0 mRNA in WT and
mutant 2E4 and I5 cells determined by RT-qPCR. qPCR primers amplify shared regions
of U17A and U17B.
D. Cells treated for 16 h with PALM or BSA. Quantification of reactive oxygen species
by CM-H2DCFDA (DCF) staining with flow cytometric analysis of 104 cells/sample. RU,
relative units.
Means + standard error (SE) for n = 3. *, p < 0.05 for indicated comparisons by unpaired
t test.
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Figure 2.2 SNHG3 lncRNA is dispensable for lipotoxicity.
A. Abundance by RT-qPCR of SNHG3 lncRNA and U17 snoRNAs in WT CHO and
2E4 cells, and in WT CHO cells stably expressing shRNA constructs targeting SNHG3
(shSNHG3) or a scrambled sequence (shSCR, control).
B. Cell death following 48 h treatment of cells in (A) with 500 µM PALM vs. BSA.
C. Abundance by RT-qPCR of SNHG3 lncRNA and U17 snoRNAs in NIH3T3 cells
transfected with LNAs targeting SNHG3 lncRNA, U17 snoRNAs, or GFP (control).
D. Cell death following 24 h treatment of cells in (C) with 400 µM PALM vs. BSA.
E. Abundance by RT-qPCR of SNHG3 lncRNA and U17 snoRNAs in NSF cells after
transfection with U17 or GFP LNAs.
F. Cell death following 48 h treatment of cells in (D) with 1000 µM PALM vs. BSA.
Means + SE for n = 3. *, p < 0.05 for indicated comparisons by unpaired t test.
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Figure 2.3 Snhg3 deficiency protects against oxidative stress.
A. WT and 2E4 cells treated for 16 h with 2 mM H2O2. NT, non-treated control. Cell
death by propidium iodide and annexin V-GFP staining with flow cytometric analysis
of 104 cells/sample.
B. Cells treated for 1 h with 2 mM H2O2. Quantification of reactive oxygen species by
DCF staining with flow cytometric analysis of 104 cells/sample.
C. RT-qPCR quantification of SNHG3 lncRNA and U17A/B snoRNAs in normal skin
fibroblasts (NSF) following transfection with GFP or U17 LNAs for 24 h.
D. Cell death, measured by propidium iodide staining, in NSF cells transfected with
GFP or U17 LNAs for 24 h and then treated for 16 h with 750 µM H2O2
Means + SE for n = 3-4. *, p < 0.05 for indicated comparisons by unpaired t test.
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Figure 2.4 2E4 mutant cells display altered redox state.
A-C. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantification of
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in WT and 2E4 cells.
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24

Chapter 3:
Metabolic rewiring in Snhg3 mutants
3.1 INTRODUCTION
Energy homeostasis requires a precise balance between nutrient uptake, catabolism, and
synthesis. During prolonged nutrient excess, compensatory metabolic changes can lead
to organ and tissue dysfunction, oxidative stress, and cell death. Such perturbations in
cellular metabolism are defining features of obesity, diabetes, and NAFLD.
Hyperglycemia, often secondary to insulin resistance in the setting of inadequate
pancreatic b-cell compensation, induces damage at the organ and cellular levels.
Advanced glycation end products, produced via non-enzymatic glycosylation of proteins
and lipids, deposit within the endothelium of blood vessels.11 The resulting activation of
macrophages induces inflammation and contributes to endothelial dysfunction.10 Excess
cellular metabolism of glucose triggers ER stress, promotes mitochondrial ROS
production, and activates tumor suppressors and cell death pathways.101 Elevated
circulating lipids, particularly FFAs, promote insulin resistance, oxidative stress, and
production of inflammatory cytokines.24,57 Recent evidence has also demonstrated that
chronic consumption of excessive amino acids exacerbates atherosclerosis through
macrophage activation and endothelial damage.102

Lipotoxicity involves intricate crosstalk between metabolic pathways of macronutrients,
including lipids, glucose, and amino acids. While lipid excess promotes ER stress,
oxidative damage, and inflammation, such responses are modulated by the presence of
25

other nutrients. In many cell types, glucose enhances lipotoxicity. Glucose and saturated
fatty acids synergistically cause cell death in cultured pancreatic b-cells.103,104 In
adipocytes, palmitate-induced ROS and inflammatory cytokine production are
dramatically augmented by the presence of glucose,105 and glucose injections promote
increased hepatic oxidative stress in mice fed high-fat diets.106 Hyperglycemia induces
transcription factors involved in lipogenesis and increases malonyl-coA production,
leading to inhibition of carnitine palmitoyl-transferase and exacerbating lipid
accumulation.107 Glucose can also suppress lipid catabolism through inhibition of PPARa signaling.108 Excess amino acids, particularly glutamine and branched chain amino
acids, modulate lipotoxicity. Glutamine dramatically augments lipid-induced oxidative
stress in macrophages and may contribute to the effects of high protein diets on
atherosclerosis.109-111

Given that nutrient excess plays a dominant role in the pathogenesis of the metabolic
syndrome, interventions that boost nutrient metabolism have long been sought as
treatments for diabetes and obesity. Therapies that upregulate mitochondrial biogenesis
and b-oxidation, including metformin and uncoupling agents, promote weight loss,
improve glucose tolerance, and reduce hepatic steatosis. Enhancing peripheral glucose
disposal through increasing mitochondrial glucose oxidation and glucose uptake, a
mechanism utilized by thiazolidinediones, dramatically improves insulin sensitivity.
Common to these treatments is a fundamental rewiring of cellular macronutrient
metabolism toward mitochondrial oxidation. However, the clinical benefits of many of
these drugs are mitigated by adverse effects and they are contraindicated in patients with
liver, kidney, and heart failure. There is thus a need to elucidate mechanisms that regulate
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the metabolic fates of glucose, lipids, and amino acids during nutrient excess to identify
novel targets that mediate metabolic remodeling.

3.2 RESULTS
3.2.1 Glycolytic flux in Snhg3 mutant cells.

Snhg3 mutant cells show higher levels of GSH and NADPH and are resistant to lipid- and
H2O2-induced oxidative stress (see Chapter 2). Glucose flux through glycolysis and the
pentose phosphate pathway (PPP) are major contributors to cellular redox balance and
NADPH levels.112 Augmented PPP activity accompanies the dramatic shift toward aerobic
glycolysis exhibited by many tumors, known as the Warburg effect, contributing to
increased NADPH production and oxidative stress resistance.113 This led us to
hypothesize that these pathways may also be upregulated in 2E4 cells. However, 2E4
cells showed significantly lower glucose-stimulated extracellular acidification rates, often
used as a proxy for glycolysis-driven lactate efflux, compared to WT cells despite similar
rates of glucose uptake (Figure 3.1). We also assessed the abundance of glycolysis
metabolites (Figure 3.2A) by liquid chromatography-mass spectrometry (LC-MS). While
there was a 20% increase in 2/3-phosphoglycerate levels in 2E4 cells compared to WT,
other metabolites in the glycolysis pathway were unchanged (Figure 3.2B). Stable
isotope tracer analysis with uniformly
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C-labeled ([U-13C]) glucose did not reveal any

significant differences in the enrichment of glucose-6-phosphate, glyceraldehyde
phosphate, 2/3-phosphoglycerate, or lactate (Figure 3.2C-F). PPP metabolites were not
reliably detected in either cell line, consistent with prior tracing studies showing low PPP
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activity in CHO cell lines during the growth phase.114 Hence, the contribution of this
pathway to cellular redox balance in 2E4 cells could not be assessed by these methods.

3.2.2 Oxidative glucose metabolism is elevated in 2E4 cells.

Mitochondrial metabolism regulates cellular redox balance through production of reducing
equivalents, generation of GSH precursors, and neutralization of ROS. Electron transport
chain integrity is also particularly critical in mounting defenses against H2O2
cytotoxicity.115 We reasoned that increased mitochondrial substrate oxidation could
contribute to changes in redox balance and oxidative stress resistance. To assess
whether Snhg3 mutant cells have alterations in oxidative metabolism, we first quantified
oxygen consumption rates (OCR) in WT and 2E4 cells in response to glucose.
Respiration on glucose was increased in 2E4 compared to WT cells (Figure 3.3A).
Oligomycin-sensitive respiration, proportional to ATP turnover, and FCCP-induced
respiration, reflective of maximal oxidative capacity, were also higher in 2E4 cells than in
WT cells (Figure 3.3B). In addition, pool sizes of citrate and a-ketoglutarate were greater
in 2E4 cells than WT cells (Figure 3.3C, D). To determine whether this increased glucose
oxidation represented augmented flux of glucose into the TCA cycle, we repeated
metabolic tracing with [U-13C]glucose in WT and 2E4 cells. 2E4 cells demonstrated
significant increases in
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C-enrichment of citrate and a-ketoglutarate (Figure 3.3E, F).

Consistent with the notion that increased TCA metabolism augments GSH synthesis, we
observed increased [U-13C]glucose enrichment in glutamate and GSH in 2E4 mutants
relative to WT cells (Figure 3.4). Together, these data demonstrate that Snhg3 loss-of-
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function rewires mitochondrial glucose metabolism toward increased oxidative
phosphorylation and GSH biogenesis.

3.2.3 U17 snoRNA haploinsufficiency upregulates fatty acid and glutamine
oxidation.

To ascertain whether this increased oxidative phosphorylation was specific to glucose,
we quantified metabolism of additional substrates that feed into the TCA cycle. Consistent
with a general upregulation of oxidative phosphorylation, respiration on glutamine was
also significantly higher in 2E4 cells compared to WT cells (Figure 3.5A). In fatty acid
oxidation assays using radiolabeled palmitate, 2E4 mutants liberated significantly more
14

CO2 from [1-14C]palmitate than WT cells, despite similar fatty acid uptake between these

cell lines (Figure 3.5B, C). Enhanced fatty acid oxidation was associated with lower
cellular triglyceride content under both basal and lipotoxic conditions (Figure 3.5D). Thus,
in addition to changes in cellular redox regulation, 2E4 cells have an enhanced capacity
to dispose of excess fatty acids under lipotoxic conditions.

3.2.4 Reduced Snhg3 expression blunts mitochondrial oxidative stress

Mitochondrial metabolism contributes to oxidative stress defenses through production of
reducing equivalents and glutathione precursors. Deficiencies electron transport chain
complexes result in profound sensitivity to oxidative stress. Consistent with this notion,
we observe greater abundance of cellular NAD+ and NADH in 2E4 cells (Figure 3.6A, B),
as well as enhanced glutathione synthesis in 2E4 cells (Figure 3.4). NAD+ pool size is
also linked to mitochondrial function during oxidative stress.116 Accordingly, 2E4 cells are
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protected from mitochondrial ROS following challenge with H2O2 (Figure 3.6C). The
reprogramming of mitochondrial metabolism in 2E4 cells occurred in the absence of
changes in expression of fatty acid oxidation and TCA cycle enzymes, mitochondrial
abundance, or gross mitochondrial morphology (Figure 3.7).

3.3 CONCLUSIONS
Metabolic stress, including lipotoxicity and oxidative stress, can lead to broad
perturbations in key metabolic pathways. In this chapter, we have demonstrated that
metabolic stress-resistant Snhg3 mutant cells have rewired mitochondrial metabolism
that impacts several substrates. This reprogramming is characterized principally by
augmented mitochondrial oxidation of glucose, lipids, and amino acids and is associated
with increased NAD pools and reduced mitochondrial oxidative stress. Moreover,
increased mitochondrial glucose consumption contributes to antioxidant production
through funneling of a-ketoglutarate to glutathione biogenesis. These findings provide
evidence for a mechanistic link between snoRNAs, nutrient metabolism, and resistance
to metabolic stress. Given the success of interventions that augment nutrient oxidation in
the treatment of the metabolic syndrome, U17 snoRNAs may serve as novel therapeutic
targets to improve adverse metabolic changes in diabetes and obesity.
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A., B. Extracellular acidification rates (ECAR) in WT and 2E4 cells. 5 mM glucose was
injected into wells containing 4.0 x 104 cells in Seahorse base medium supplemented
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C-F. Isotopologue distribution analysis of G6P (C), GAP (D), 2/3-PG (E), and LAC (F)
determined by stable isotope tracing with [U-13C]glucose over 6 h in WT and 2E4 cells.
Means + SE for n = 3. *, p < 0.05 for WT vs. 2E4 by unpaired t test.
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Figure 3.3 Glucose oxidation in enhanced in 2E4 cells.
A., B. Seahorse XF analyzer measurement of oxygen consumption rates (OCR) in
WT and 2E4 cells in XF base medium following introduction of 5 mM glucose and serial
injections of 1.5 µM oligomycin, 2 µM FCCP, and 2 µM antimycin A. ATP turnover,
maximal respiration (max) and proton leak are shown in (B).
C. Schematic of TCA cycle metabolites.
D. Abundance of TCA cycle intermediates (citrate, a-ketoglutarate (a-KG), malate,
succinate), pyruvate, and lactate quantified by LC-MS and normalized to cellular
protein content.
E., F. Isotopologue distribution analysis of citrate (E) and a-KG (F) determined by
stable isotope tracing with [U-13C]glucose over 6 h in WT and 2E4 cells.
Means ± SE for n = 3. *, p < 0.05 for WT vs. 2E4 by unpaired t test.
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Figure 3.4. Synthesis of glutathione from glucose is enhanced in 2E4 cells.
A., B. Isotopologue distribution analysis of glutamate (A) and glutathione (GSH, B)
determined by stable isotope tracing with [U-13C]glucose over 6 h in WT and 2E4
cells. Means + SE for n = 3. *, p < 0.05 for WT vs. 2E4 by unpaired t test.
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Figure 3.5. Augmented glutamine and fatty acid oxidation in 2E4 cells.
A. Seahorse XF analyzer quantification of OCR in WT and 2E4 cells in XF base medium
following introduction of 2 mM glutamine. Injections of oligomycin, FCCP, and antimycin
were used for calculation of ATP turnover, maximal respiration, and proton leak.
B. Fatty acid oxidation quantified by liberation of 14C-CO2 from WT and 2E4 cells
incubated with [1-14C]palmitate for 6 h.
C. BODIPY-labeled fatty acid uptake over 1 min, quantified by flow cytometric analysis
of 104 cells/sample.
D. Quantification of cellular triglyceride (TG) in WT and 2E4 cells treated with BSA or
PALM for 16 h.
Means + SE for n = 3-4. *, p < 0.05 for WT vs. 2E4 or for comparisons indicated by
unpaired t test.
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A. RT-qPCR expression of TCA cycle enzymes in WT and 2E4 cells. CS, citrate
synthase; IDH2, isocitrate dehydrogenase 2; MDH2, malate dehydrogenase 2; OGDH,
2-oxoglutarate dehydrogenase; SDHA, succinate dehydrogenase subunit A.
B. RT-qPCR quantitation of enzymes involved in fatty acid oxidation in WT and 2E4
cells. FAT, fatty acid translocase; ACADL, acyl-coA dehydrogenase-long chain;
CPT1A, carnitine palmitoyltransferase 1A; HADH, hydroxyacyl-CoA dehydrogenase;
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in WT and 2E4 cells.
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mitochondrial targeting sequence. Scale bar, 5 µM.
Means + SE for n = 3. *, p < 0.05 for WT vs. 2E4 by unpaired t test
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Chapter 4:
rRNA processing in Snhg3 mutants
4.1 INTRODUCTION
The eukaryotic ribosome is a massive molecular structure containing 79 ribosome
proteins and four distinct rRNA species that are organized within two subunits. The small
subunit (40S) contains the 18S rRNA and 33 ribosomal proteins, while the large subunit
(60S) is composed of the 28S, 5.8S, and 5S rRNAs and 46 ribosomal proteins.117
Ribosome biogenesis consumes substantial energy in dividing cells and rRNA species
account for more than 80% of total cellular RNA.118 Given this complex structure,
ribosome biogenesis requires hundreds of factors acting in concert, many of which are
highly conserved among eukaryotic organisms.

Production of mature ribosomes begins in the nucleolus, where rDNA is transcribed by
RNA polymerase I to generate the 47S precursor rRNA, a single transcript that contains
the 28S, 18S, and 5.8S rRNAs. The 5S rRNA is encoded separately and is transcribed
by RNA polymerase III. Within the 47S transcript, mature rRNA sequences are separated
by the internal transcribed spacers 1 and 2 (ITS1 and 2) and flanked by the 3’ and 5’
external transcribed spacers (ETS). This pre-rRNA associates co-transcriptionally with
numerous

ribosomal

proteins,

pre-ribosomal

factors,

and

small

nucleolar

ribonucleoprotein particles (snoRNPs) that assist in modification and folding of the
nascent pre-rRNA molecule.117 During this process, transcribed spacer sequences are
removed through the action of multiple endonucleases and exonucleases, and the
38

liberated rRNA species associate with additional ribosomal proteins before export to the
cytoplasm where the maturation process is completed.

snoRNAs play critical roles in pre-rRNA processing and rRNA maturation by mediating
cleavage of pre-rRNA and guiding nucleotide modifications that facilitate rRNA folding,
stability, and assembly within ribosome subunits.81 U17 snoRNAs are essential for
processing of the 5’ ETS within the 47S transcript and 18S rRNA maturation. In yeast, the
U17 homolog, snR30, is required for cell viability and facilitates cleavage of the 35S prerRNA at the A0, A1, and A2 sites within the 5’ ETS.119 Deletion of snR30 inhibits 18S
rRNA production and causes accumulation of the 35S rRNA transcript. In mammalian
cells, U17 snoRNAs also mediate 5’ ETS cleavage in concert with the U3, E3, U14
snoRNAs, but their role here is less well defined.120

As a primary driver of proliferation and energy consumption, ribosomal biogenesis is
tightly controlled by signaling pathways that regulate cellular metabolism. Chief among
these is the mammalian target of rapamycin (mTOR) kinase complex, which integrates
growth factor and nutrient signaling with cellular metabolism and proliferation. In response
to growth factors such as insulin, mTOR phosphorylates numerous downstream effectors
to augment nutrient utilization and energy production to drive proliferation. A central
feature of this response is enhanced ribosomal biogenesis and translation capacity.
mTOR signaling activates all steps of ribosomal biogenesis, including transcription of
rDNA and ribosomal proteins, rRNA processing, and assembly of new ribosomal
subunits.121 In the cytoplasm, mTOR promotes phosphorylation of ribosomal proteins to
drive formation of polysomes and initiation complex formation, leading to a dramatic
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upregulation in protein synthesis. Interestingly, alterations in ribosomal biogenesis can
also have feedback regulation on the mTOR signaling axis. mTOR complex 2 (mTORC2)
activation occurs on mature ribosomes, and abrogation of rRNA processing leads to
compensatory mTOR complex 1 (mTORC1) activation and assembly of polysomes.122-124
The mechanisms mediating this feedback are not well understood.

The mTOR axis is also a principal regulator of cellular metabolism and nutrient utilization.
Signaling through mTOR increases glucose uptake and flux through glycolysis and
pentose phosphate pathways.125 Similarly, mTOR augments amino acid catabolism and
promotes b-oxidation of fatty acids.118 This energy production is powered in part by an
mTOR-mediated translational program that selectively increases association of
mitochondrial transcripts with polysomes, promoting their translation to enhance
mitochondrial oxidative capacity.126 Additionally, mTOR coordinates transcription of
numerous enzymes involved in glucose and fat metabolism.118 Overall, this metabolic
rewiring generates more reducing equivalents, in the form of NADH, FADH2, and NADPH
that fuel the electron transport chain and cellular antioxidant systems. Indeed, mTOR
activation during oxidative stress response generates glutathione and NADPH that
reduces propagation of reactive oxygen species.127 Oxidative stress also triggers mTORmediated phosphorylation of AKT to suppress induction of apoptosis.128 However, the role
mTOR-dependent metabolic rewiring in protection from nutrient excess has not been
thoroughly examined.
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4.2 RESULTS
4.2.1 Altered kinetics of rRNA production in 2E4 cells.

Although the canonical function of the box H/ACA class of snoRNAs is to direct
isomerization of uridine to pseudouridine on nascent rRNAs and tRNAs, vertebrate U17
and its yeast homolog snR30 are instead required for cleavage of pre-rRNAs during
production of mature rRNAs.129 Nonetheless, we did not observe altered steady state
rRNA abundance in 2E4 cells, which are haploinsufficient for U17 snoRNAs (Figure 4.1A,
B). To evaluate further the effects of U17 snoRNA deficiency on rRNA biosynthesis, we
performed pulse-chase experiments with 5-ethynyl uridine (EU) to label newly
synthesized rRNAs. During a 30 min pulse, compared to WT cells, 2E4 cells showed
increased label incorporation into the 47S precursor species (Figure 4.1C). During a 6 h
chase, the proportion of labeled 28S and 18S products steadily increased in WT cells
(Figure 4.1D), whereas the proportion of labeled products failed to increase in 2E4 cells
over the same time course (Figure 4.1E). These data are consistent with the notion that
steady state rRNA abundance is maintained in 2E4 cells in part through increased
transcription of precursor rRNAs.

4.2.2 mTOR signaling is activated in 2E4 cells.

Ribosome biogenesis is a major energy requiring pathway that is regulated by mTOR. In
turn, defects in rRNA production can activate mTOR signaling.124 Because mTOR is also
a master regulator of cellular energetics and metabolism,118 we hypothesized that mTOR
signaling might serve as a link between U17 snoRNAs and changes in cellular
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metabolism. Thus, we assessed signaling downstream of mTOR in WT and 2E4 cells. S6
kinase (S6K) phosphorylation at T389, a canonical target of mTORC1 signaling, was
upregulated in 2E4 compared to WT cells after 16 h serum deprivation followed by
administration of insulin (Figure 4.2A). Expression of mTOR was also increased in 2E4
mutants (Figure 4.2B). Consistent with the known function of mTOR to relieve inhibition
of translational elongation and stimulate assembly of monosomes into polysomes, we
observed a shift in the distribution of ribosomes toward polysomes in 2E4 cells compared
to WT cells (Figure 4.2C). Similarly, we observed that LNA-mediated knockdown of U17
snoRNAs in normal human skin fibroblasts led to enhanced AKT phosphorylation and
increased mTOR expression (Figure 4.3). Together, these results demonstrate that
signaling pathways downstream of mTOR are activated by decreased U17 snoRNA
expression.

4.2.3 Oxidative stress resistance and metabolic rewiring in 2E4 cells requires
mTOR activity.

AKT phosphorylation at S473, mediated by mTORC2, is increased during oxidative stress
where it orchestrates pro-survival responses.122,130 We observed increased AKT S473
phosphorylation in 2E4 relative to WT cells under both basal growth conditions and during
treatment with H2O2 (Figure 4.4A). To determine the contributions of this increased
mTOR activity to the phenotypes of U17 snoRNA-deficient cells, we treated cells with 250
nM torin 1 to inhibit the mTOR signaling axis. Torin 1 treatment completely abolished
H2O2 resistance in 2E4 cells, indicating that mTOR signaling is required for this phenotype
(Figure 4.4B). Similarly, torin 1 eliminated the increased glucose oxidation observed in
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2E4 cells relative to WT cells (Figure 4.5), consistent with reports that mTOR activity
supports enhanced oxidative metabolism. Since torin 1 potently inhibits both mTORC1
and mTORC2 signaling, these experiments cannot distinguish which signaling complex
mediates the metabolic rewiring and oxidative stress resistance observed in Snhg3
mutants.

4.2.4 mTOR inhibition exacerbates rRNA processing defects during U17 snoRNA
deficiency.

mTOR signaling is a principal regulator of rRNA processing and ribosomal biogenesis.
Defects in rRNA synthesis machinery can also promote mTOR activity as a compensatory
response to maintain cellular growth and energy homeostasis, although the mechanisms
of this feedback response are not entirely characterized. We hypothesized that increased
mTOR signaling might contribute to maintaining rRNA production during U17 snoRNA
deficiency. To test this question, we knocked down U17 snoRNAs in WT CHO cells and
treated with torin 1. While U17 snoRNA deficiency did not significantly reduce rRNA
abundance in vehicle-treated cells, administration of torin 1 dramatically reduced rRNA
content in cells with U17 snoRNA knockdown (Figure 4.6). These findings indicate that
maintenance of rRNA production during U17 snoRNA deficiency requires mTOR
signaling.
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4.2.5 Deletion of Rpl13a snoRNAs does not alter rRNA production or mTOR
signaling.

snoRNAs encoded by the Rpl13a locus are required for lipotoxicity and oxidative stress.77
To determine whether altered rRNA production and mTOR activity is a common feature
of snoRNA deficiency, we examined these parameters in primary hepatocytes harvested
from mice with germline knockout of the four Rpl13a snoRNAs (Rpl13a snoless).89 Like
U17 snoRNA-deficient cells, Rpl13a snoless hepatocytes maintained normal 28S and
18S rRNA abundance; however, we did not observe upregulation of mTOR activity
(Figure 4.7). This suggests that U17 snoRNAs and Rpl13a snoRNAs employ different
mechanisms to modulate metabolic stress responses.

4.2.6 U17 snoRNA knockdown in vivo recapitulates key phenotypes of 2E4 cells.

To extend our findings in vivo, we examined the effects of U17 snoRNA loss-of-function
in the liver, where metabolic and oxidative stress responses highly characterized and are
critical for organ homeostasis. We injected mice with two LNAs targeting U17 snoRNAs
or GFP (control). Relative to control LNAs, U17-1 and U17-2 LNAs achieved 37% and
68% knockdown of U17 snoRNAs, respectively (Figure 4.8A). In chow-fed animals,
knockdown of U17 snoRNAs in the liver led to higher NADPH levels, a lower
NADP+:NADPH ratio, and a lower GSSG:GSH ratio, indicative of more robust antioxidant
defenses (Figure 4.8B-E and Figure 4.9).

We further examined in vivo effects of knockdown with U17-2 LNA, which is more potent
and did not alter expression of SNHG3 lncRNA (Figure 4.8A). Knockdown of U17
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snoRNAs in the liver increased abundance of 47S pre-RNA but did not impact abundance
of 28S and 18S product species, leading to a higher 47S to 18S rRNA ratio (Figure 4.10).
This suggests that impaired rRNA processing causes a compensatory increase in
precursor species in order to maintain sufficient levels of mature rRNAs. U17 snoRNA
knockdown increased S473 AKT phosphorylation and elevated mTOR expression in the
livers of ad libitum-fed mice (Figure 4.11A, B). Changes in mTOR signaling were
accompanied by a concomitant shift of ribosome populations toward polysomes in the
livers of mice treated with U17 LNAs (Figure 4.11C, D). These findings demonstrate that
selective knockdown of U17 snoRNAs in vivo is sufficient to recapitulate central
phenotypic aspects of Snhg3 mutant cells.

4.3 CONCLUSIONS
Links between U17 snoRNAs and rRNA processing and between mTOR activation and
ribosomal biogenesis are well established. In this chapter, we build upon these findings
and demonstrate that changes in U17 snoRNA-mediated rRNA processing effect
alterations in cellular metabolism through mTOR signaling. We show through metabolic
labeling experiments that haploinsufficiency of U17 snoRNAs reduces efficiency of rRNA
processing in 2E4 cells. This phenotype is characterized by accumulation of pre-rRNA
and altered production of both 18S and 28S rRNAs. While complete U17 snoRNA
deficiency abolishes 18S rRNA synthesis, cells with partial reduction in U17 snoRNA
expression produce normal amounts of 28S and 18S rRNA through activation of mTOR
signaling, which functions to boost transcription of pre-rRNA and accelerate rRNA
processing. In 2E4 cells, increased mTOR activation is required for oxidative stress
45

resistance and augmented mitochondrial glucose oxidation. We also show that
knockdown of U17 snoRNAs in the liver alters rRNA processing and activates mTOR.
These findings establish a critical mechanism through which snoRNA deficiency can lead
to metabolic reprogramming.
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Figure 4.1. U17 snoRNA haploinsufficiency alters kinetics of rRNA processing.
A., B. Representative bioanalyzer traces of total RNA collected from WT and 2E4 cells.
Quantitation of rRNA peak area is shown in (B).
C. RT-qPCR quantified abundance of 5-ethynyl uridine (5-EU)-labeled 47S rRNA
species normalized to actin mRNA following a 30 min pulse with 0.4 mM 5-EU.
D., E. RT-qPCR quantified abundance of EU-labeled 47S, 28S, and 18S rRNA during
a 6 h chase period in WT (D) and 2E4 cells (E).
Means + SE for n = 3-4. *, p < 0.05 for WT vs. 2E4 by unpaired t test.
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Figure 4.2. Upregulated mTOR signaling in 2E4 cells.
A. Representative immunoblot of S6 kinase (S6K) and phospho-S6K (T389) in WT
and 2E4 cells cultured for 16 h in 5% FBS medium (F), serum-free medium (S), or
serum-free medium followed by treatment with 250 nM insulin for 30 minutes (S+I).
GAPDH is shown as a loading control. Graph shows quantification of ratio of
phosphorylated S6K (P-S6K) to total S6K following insulin treatment from independent
experiments.
B. Representative immunoblot of mTOR protein in WT and 2E4 cells. Graph shows
quantification from independent experiments.
C. Representative polysome profiles of WT and 2E4 cells. Traces of absorbance at
254 nm with 40S, 60S, and 80S peaks for the respective ribosome subunits and
monosomes. Graph (right) shows quantification of the ratio of polysome to monosome
peak areas (P/M ratio) in WT and 2E4 cells (n = 5 for each).
Means + SE for n = 3-5. *, p < 0.05 by unpaired t test for WT vs. 2E4.
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B., C. Immunoblot of mTOR, phospho-AKT (S473), and AKT in NSF cells transfected
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shown as a loading control. Quantification of P-AKT/AKT and mTOR is shown in (C).
Means + SE for n = 3-4. *, p < 0.05 by unpaired t test for comparisons indicated.
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Figure 4.6. mTOR inhibition exacerbates rRNA production defects during U17
snoRNA deficiency.
A. RT-qPCR quantified abundance of U17A/B snoRNAs and SNHG3 lncRNA in WT
CHO cells treated with 25 nM U17 or GFP LNAs (control) for 24 h.
B. RT-qPCR quantified abundance of 47S, 28S, and 18S rRNA species in WT cells
transfected with U17 or GFP LNAs following 24 h treatment with 250 nM torin 1.
C., D. Representative bioanalyzer traces of total RNA collected from WT cells
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Means + SE for n = 3. *, p < 0.05 by unpaired t test for comparisons indicated.
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Figure 4.7. mTOR signaling and rRNA production are not altered in Rpl13a
snoless primary hepatocytes.
A. Representative immunoblot of mTOR signaling in primary hepatocytes collected
from WT and Rpl13a snoless littermates following incubation in plating medium (P), 3
h starvation in HBSS (S), 3 h starvation in HBSS followed by 30 min incubation in
complete amino acid cocktail (S/A), or 3 h starvation in HBSS followed by 30 min
incubation in plating medium (S/P). Quantification of pAKT/AKT, p4EBP1/4EBP1, and
pS6/S6 is shown in graphs at right.
B. Quantification of rRNA peak area in total RNA collected from primary hepatocytes
harvested from WT and Rpl13a snoless littermates.
Means + SE for n = 3-5.
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Chapter 5:
U17 snoRNAs regulate lipotoxicity in vivo

5.1 INTRODUCTION
In diabetes and obesity, nutrient overload drives adipose expansion and deposition of
lipids within the heart, skeletal muscle, and liver. While adipocytes have tremendous
capacity to safely sequester lipids within TG stores, a function that mitigates lipotoxicity,
non-adipose tissues have a limited TG storage capacity that is quickly overwhelmed in
settings of chronic nutrient excess.31,32 This ectopic TG deposition is a hallmark of lipid
overload, indicating “overflow” from adipose depots.32 As a result, toxic lipids and their
metabolites that cannot be esterified as TG accumulate and promote ER stress, oxidative
damage, and cell death.

Beyond cell autonomous effects, ectopic lipid accumulation and lipotoxicity can have
profound consequences for systemic metabolic homeostasis. Many patients who are
obese demonstrate aberrant glucose homeostasis, characterized by hyperglycemia and
glucose intolerance, that is secondary to reduced insulin sensitivity in skeletal muscle and
adipose depots.10 Hepatic insulin resistance, resulting in failure to suppress
gluconeogenesis, also contributes to hyperglycemia in type 2 diabetes.131 Within these
tissues, lipid excess dampens insulin-mediated glucose uptake directly, via inhibition of
insulin receptor substrates, and indirectly through inducing inflammation and oxidative
stress and impairing mitochondrial metabolism.22,23,28 In this way, lipotoxicity is a critical
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mechanistic link between obesity and type 2 diabetes. Early in the course of the metabolic
syndrome, euglycemia is maintained through augmented insulin release from pancreatic
islets.10 As insulin resistance progresses, compensatory b-cell insulin release is no longer
sufficient and hyperglycemia develops. Chronic elevation of blood glucose promotes
endothelial damage and many resulting sequelae of diabetes such as retinopathy,
glomerulopathy, and atherosclerosis.11,12

Insulin resistance contributes to the pathogenesis of nonalcoholic fatty liver disease
(NAFLD). Hyperinsulinemia stimulates hepatic lipogenesis and lipoprotein protein
production, causing steatosis.20 Endogenous fat accumulation is compounded by
increased delivery of free fatty acids to hepatocytes, a consequence of failure of insulin
to appropriately suppress lipolysis in adipose tissue.57 While NAFLD begins as simple
hepatic steatosis, it can evolve to nonalcoholic steatohepatitis (NASH), which is
characterized by disruption of normal hepatocyte structure (ballooning), hepatocyte
death, inflammation, and fibrosis.63 In a subset of NASH patients, fibrosis can progress
to cirrhosis and hepatocellular carcinoma. The mechanisms that cause progression of
steatosis to hepatitis and fibrosis are not well understood. Given our observations on
effects of knockdown of U17 snoRNA on cellular and hepatic metabolic homeostasis, we
sought to examine the function of U17 snoRNAs in hepatic lipid accumulation and
systemic glucose homeostasis in models of NAFLD.
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5.2 RESULTS
5.2.1 Knockdown of U17 snoRNAs ameliorates diet-induced lipotoxicity

Knockdown of U17 snoRNAs reduces lipotoxicity and oxidative stress in cultured cells.
To examine the role of U17 snoRNAs in lipid accumulation and oxidative stress in vivo,
we tested whether U17 snoRNA knockdown alters liver injury in response to a diet that
causes hepatic steatosis, oxidative stress, and hepatocyte damage. We used the
methionine- and choline-deficient diet (MCD) for these studies because of its ability to
rapidly induce these abnormalities in the liver.132 We administered LNAs targeting U17
snoRNAs or control LNAs targeting GFP to C57BL6/J male mice and placed these
animals on the MCD for 3 weeks. LNAs achieved effective knockdown of U17 snoRNAs
in mice on both control and MCD diets (Figure 5.1A). In animals receiving control diet,
expression of the SNHG3 lncRNA and U17 snoRNAs were induced by the MCD diet,
indicating that this locus is responsive to lipid overload in vivo (Figure 5.1A). MCD diet
feeding caused similar weight loss and elevations of plasma transaminases in animals
that received control and U17 LNAs (Figure 5.1B, C). Thus, knockdown of U17 snoRNAs
did not prevent overall changes in body mass or systemic markers of hepatocyte cell
death.

Liver sections of MCD-fed control knockdown animals showed marked steatosis and
inflammatory mononuclear and polymorphonuclear (PMN) infiltrates (Figure 5.2). Less
lipid accumulation and fewer PMNs were apparent in liver tissue of MCD-fed animals with
U17 snoRNA knockdown (Figure 5.2). Overall, F4/80 staining intensity increased in
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animals on the MCD diet but was not affected by U17 snoRNA knockdown (Figure 5.3).
However, the abundance of crown-like structures of F4/80 positive cells surrounding
dying hepatocytes, which are characteristic of steatohepatitis,133 was decreased with U17
snoRNA knockdown compared to control animals on the MCD diet (Figure 5.3).
Biochemical analyses confirmed that knockdown of U17 snoRNAs significantly reduced
hepatic triglyceride content (Figure 5.4A). Furthermore, cholestane-3b, 5a, 6b-triol and
7-ketocholesterol, robust lipid markers of tissue oxidative stress,134 were diminished by
U17 snoRNA knockdown in animals on the MCD diet (Figure 5.4B, C). Collectively, these
findings suggest that at the tissue level, knockdown of U17 snoRNAs mitigated oxidative
damage and inflammation in the liver.

Treatment with the MCD diet for this short duration produced minimal fibrosis (Figure
5.5). However, transcripts associated with stellate cell activation and fibrosis, including
collagens and matrix remodeling proteins, were significantly increased in MCD-fed
animals that received control oligos relative to MCD-fed animals receiving U17 LNAs
(Figure 5.6). The observations that knockdown of U17 snoRNAs in vivo reduced steatosis
and markers of tissue damage are consistent with a model in which depletion of U17
snoRNAs alters lipid metabolism in vivo and protects against lipotoxicity at the tissue
level.

5.2.2 U17 snoRNAs mediate glucose homeostasis during high-fat diet feeding

While the MCD diet is a robust model of hepatic lipotoxicity, animals lose weight and do
not develop insulin resistance. As obesity and insulin resistance are critical factors in the
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pathogenesis of human NAFLD, we turned to additional models to gain insight into the
role of U17 snoRNAs on these metabolic parameters and better define their function in
the metabolic syndrome. We next treated mice with U17 or control LNAs during a 4-week
challenge with a 60% fat diet (high-fat diet, HFD). As a control, mice were maintained on
10% fat diet (low-fat diet, LFD). Compared to LFD animals, HFD animals exhibited weight
gain and enlargement of inguinal and subcutaneous adipose depots while liver mass was
unchanged (Figure 5.7). These parameters were largely unaffected by treatment with
U17 LNAs, indicating that U17 snoRNAs do not prevent obesity or alter body composition
in response to HFD.

We performed dynamic metabolic testing to determine whether treatment with U17 LNAs
impacts systemic glucose homeostasis during HFD. Relative to LFD controls, HFD
animals

exhibited

markedly

impaired

peripheral

glucose

disposal

during

an

intraperitoneal glucose tolerance test (GTT). HFD animals receiving U17 LNAs showed a
modest improvement in glucose tolerance compared to counterparts receiving control
LNAs, with a strong trend for decreased GTT area-under-the-curve (p = 0.06) (Figure
5.8A, B). Consistent with an improvement in glucose homeostasis, U17 snoRNA
knockdown significantly improved insulin-mediated glucose disposal in HFD animals
(Figure 5.8C, D). Further delineation of this metabolic phenotype, including assessment
of U17 snoRNA knockdown in key tissues (liver, adipose, and skeletal muscle), and
measurement of hepatic triglycerides and oxidative stress markers, are pending due to
the COVID-19 pandemic. However, the data presented here suggest that U17 snoRNAs
play a role in regulating systemic metabolism and that modifying expression of these
noncoding RNAs may alter the course of the metabolic syndrome.
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5.3 CONCLUSIONS
Here, we show that deficiency of U17 snoRNAs reduces lipid accumulation and oxidative
stress in vivo in response to the MCD diet. Over the short duration of this study, we did
not observe substantial fibrosis. However, U17 snoRNA knockdown blunted MCD dietinduced expression of stellate cell activation markers. Limitations of the MCD diet in
general and the short duration of our study notwithstanding, our findings suggest that
deficiency of U17 snoRNA alters hepatic metabolism in ways that impact the development
of NAFLD. Consistent with this notion, we found that U17 snoRNA knockdown
ameliorates glucose tolerance and improves glucose disposal in response to insulin in
the setting of diet-induced obesity. Together, these studies uncover a novel function for
U17 snoRNAs in metabolic homeostasis in diet-induced disease models.
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Figure 5.1 Snhg3 expression is induced by MCD diet.
A. RT-qPCR quantification of SNHG3 and U17 snoRNAs in mice treated with GFP or
U17 LNAs during feeding with methionine- choline-deficient (MCD) or control diets for
3 weeks.
B. Body weights in animals fed MCD and control diets.
C. Plasma levels of alanine transaminase (ALT) and aspartate transaminase (AST) in
animals fed MCD or control diets.
Mean + SE for n = 7-11. #, p < 0.05 for MCD vs. control diet by unpaired t test; *, p <
0.05 for comparisons indicated by unpaired t test.
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Figure 5.2 U17 snoRNA knockdown reduces neutrophil infiltration in MCD diet.
A. Representative hematoxylin/eosin-stained (H/E) sections of liver tissue harvested
from mice fed MCD or control diets and treated with U17 or GFP LNAs. Arrows denote
polymorphonuclear (PMN) infiltrates. CV, central vein; scale bar, 50 µm.
B. Quantification of PMN infiltrates.
Mean + SE for n = 5-11. #, p < 0.05 for MCD vs. control diet by unpaired t test; *, p <
0.05 for comparisons indicated by unpaired t test.
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Figure 5.4 Knockdown of U17 snoRNAs reduces hepatic steatosis and oxidative
stress induced by MCD diet.
A. Quantification of liver triglycerides (TG) in animals treated with U17 and GFP LNAs
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Chapter 6:
Summary and Discussion
6.1 Summary
Over the last four decades, obesity has become a global epidemic. Its associated
conditions – diabetes, coronary artery disease, and cancer – cause millions of deaths
every year throughout the world. Critical to the pathogenesis of the metabolic syndrome
is lipotoxicity, the process through which excess fatty acids induce tissue dysfunction and
cell death. The molecular mechanisms underlying lipotoxicity are not fully understood.
Using mutant cell lines generated in a previously published genetic screen, we discovered
that the U17 snoRNAs encoded by the Snhg3 locus are critical mediators of lipotoxicity.
We establish novel links between snoRNAs, oxidative metabolism, and cellular redox
regulation. We show that cells deficient in U17 snoRNAs—generated by promoter trap
mutagenesis and independently confirmed by knockdown—are protected from lipotoxic
and oxidative stress. This resistance is associated with increased levels of the major
antioxidant, GSH, and increased cellular levels of NADPH and NADH. Mutant cells
haploinsufficient for U17 snoRNAs have increased mitochondrial oxidative metabolism
that drives GSH biogenesis.

We demonstrate that the critical link between loss of U17 snoRNAs and this metabolic
rewiring is altered kinetics of rRNA production that leads to enhanced mTOR signaling.
In cells deficient in U17 snoRNAs, mTOR signaling compensates to maintain cellular
rRNA levels, and in the process drives metabolic rewiring that confers resistance to
metabolic stress. We extend these findings in vivo by showing that selective knockdown
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of U17 snoRNAs in mice increases hepatic antioxidant capacity and confers protection
from steatosis and oxidative stress induced by the MCD diet. Moreover, U17 snoRNA
knockdown improves glucose tolerance and insulin-mediated glucose disposal in
response to high-fat feeding, although studies involving the effects of this intervention on
hepatic steatosis and oxidative stress have been delayed due to COVID-19. To our
knowledge, this work is the first to link snoRNA loss-of-function with metabolic
reprogramming and amelioration of steatohepatitis in vivo.

6.2 Lipotoxicity, oxidative stress, and metabolic rewiring
Oxidative stress is an essential feature of lipid-induced cell death. Excess lipids generate
ROS through numerous mechanisms including activation of NADPH oxidase, induction
of inflammatory signaling cascades, and impaired mitochondrial b-oxidation.34 This
oxidative stress is also required for lipid-induced cell death, as interventions that mitigate
ROS generation or propagation blunt lipotoxicity.41 Our finding that U17 snoRNA-deficient
cells are resistant to lipotoxicity and H2O2 suggests that loss of U17 snoRNAs may protect
against lipid-induced cellular injury through oxidative stress pathways.

The flux of glucose, fatty acids, and amino acids through catabolic and anabolic pathways
is an important regulator of cellular redox balance.135 While upregulated catabolism of
these macronutrients releases more ROS from the mitochondrial respiratory chain, this
process also increases production of reducing equivalents and precursors, such as
glutamate, that are required for key antioxidant pathways. Rewiring of mitochondrial
oxidative metabolism in 2E4 cells may thus protect against oxidative stress and
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lipotoxicity in several ways. First, similar to observations in cells treated with the AMPK
activator AICAR,100 increased fatty acid oxidation enables 2E4 cells to dispose of excess
fatty acid substrates through b-oxidation. Diminished cellular triglyceride stores in 2E4
cells under lipotoxic conditions reflects this enhanced utilization. Second, TCA
metabolism fuels mitochondrial ROS-neutralizing enzymes, including superoxide
dismutases, GSH peroxidases, and thioredoxins through generation of a-ketoglutarate, a
precursor for GSH synthesis, and through NADPH-producing enzymes including malic
enzyme, isocitrate dehydrogenase 2, glutamine dehydrogenase, and NADP(H)
transhydrogenase.136,137 The importance of these mitochondrial antioxidant defenses is
underscored by observations that mitochondrial dysfunction is associated with insulin
resistance, NAFLD, and development of type 2 diabetes.138-140 In the present study, we
show that the 2E4 mutant has expanded pool of citrate and a-ketoglutarate with greater
contribution of carbons from labeled glucose into these intermediates, indicative of
enhanced TCA flux. In addition, 2E4 cells show increased production of GSH and a
diminished GSSG/GSH ratio. These alterations in cellular metabolism – increased
disposal of fatty acids and augmented antioxidant capacity – therefore contribute
synergistically to metabolic stress resistance.

Changes in oxidative metabolism, like those observed in U17 snoRNA-deficient cells, can
occur through several mechanisms. Transcription factors, such as PPAR, HIF1, FOXO,
and p53, respond to intra- and extracellular signaling cues to regulate expression of
nutrient transporters and metabolic enzymes.101,141 These transcriptional networks,
particularly those in the PPAR family, are also crucial regulators of mitochondrial
biogenesis.142 The abundance of mitochondrial enzymes is also regulated post74

transcriptionally through specific translational programs. In response to mTORC1
activation, translation of several mitochondrial proteins is upregulated without overall
changes in transcript abundance.126 However, the majority of metabolic pathway
regulation takes place without changes in enzyme abundance.143 Post-translational
modifications, including phosphorylation, acetylation, and adenylation, occur through
numerous signaling cascades and are important regulators of enzyme activity. Most
enzymes also exhibit potent allosteric regulation, linking precursor and product
metabolism to regulate pathway activity.144

The mechanisms that are responsible for metabolic rewiring in U17 snoRNA-deficient
cells are not completely understood. We did not observe changes in transcript abundance
of enzymes within glycolysis, pentose phosphate pathway, b-oxidation, or TCA cycle in
2E4 cells with U17 snoRNA knockdown. Mitochondrial abundance and gross morphology
were also not altered in 2E4 cells. These data could be consistent with several
mechanistic explanations for U17 snoRNA-mediated metabolic rewiring. Translation of
specific enzymes or nutrient transporters involved in glucose, fatty acid, or amino acid
metabolism may be upregulated. This is an intriguing possibility given that U17 snoRNA
deficiency promotes mTOR activation, a known mediator of transcript-specific
translational regulation. Augmented mTOR activity, or changes in other nutrient- or
stress-sensitive signaling cascades, may also alter post-translation modification of
metabolic enzymes in the setting of U17 snoRNA deficiency. Future investigations,
including ribosome profiling and phosphoproteomics studies, will address these
hypotheses and provide additional mechanistic insight into U17 snoRNA-mediated
metabolic rewiring.
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6.3 rRNA biogenesis and cell metabolism
Synthesis of new ribosomes is critical for cell division and proliferation. It is also activated
by many non-mitogenic stimuli, including a wide range of cellular stresses, and is thus
essential even in non-dividing cells. Production of rRNA begins in the nucleolus, where
rDNA is transcribed by RNA polymerase I to generate the 47S precursor rRNA that
contains the 18S, 28S, and 5.8S rRNA species separated by internal and external
transcribed spacer sequences.117 Numerous ribosomal proteins, pre-ribosomal factors,
and small nucleolar ribonucleoprotein particles (snoRNPs) associate co-transcriptionally
and assist in modification and folding of the nascent pre-rRNA molecule.117 The regulation
and production of these additional factors occurs in concert with rRNA transcription.

To produce mature rRNA, transcribed spacer sequences are removed from the precursor
RNA transcript through the action of multiple endonucleases and exonucleases. In all
eukaryotic organisms, U17 snoRNAs facilitate these steps in rRNA processing by
mediating cleavage at multiple sites within the pre-rRNA precursor transcript. In yeast,
the U17 homolog, snR30, is required for cell viability and facilitates cleavage of the 35S
pre-rRNA at the A0, A1, and A2 sites within the 5’ ETS.83,119 Deletion of snR30 inhibits
18S rRNA production and causes accumulation of the 35S rRNA transcript.119 In
mammalian cells, U17 snoRNAs also mediate 5’ ETS cleavage in concert with the U3,
E3, U14 snoRNAs.120 Once liberated, rRNA species associate with additional ribosomal
proteins before export to the cytoplasm where the maturation process is completed.
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Given the energetic cost of rRNA biogenesis, its molecular machinery is regulated at
many levels through mechanisms tightly coordinated with metabolic pathways to ensure
a precise balance between the need for new ribosomes and energy supply. rRNA
synthesis is a principal point of regulation in ribosomal biogenesis. The rate of rRNA
transcription is determined by the activity of the RNA polymerase complex as well as
epigenetic modifications of the chromatin surrounding rDNA loci, and both mechanisms
are regulated by metabolic cues.145

A plethora of mitogenic and stress response pathways modulate activity of RNA
polymerase I. In response to growth factors, CBP, ERK, cyclin-CDKs, c-Myc, and mTOR
bind or modify subunits of the polymerase complex to augment its activity or enhance its
recruitment to rDNA loci.146 These signaling pathways also stimulate rRNA processing
and the synthesis of ribosomal proteins. By contrast, various tumor suppressors or stressinduced pathways, including p53, p14ARF, AMPK, RB, and PTEN, use similar
mechanisms to repress the activity of RNA polymerase I and rRNA synthesis.146 Energy
status also controls rRNA transcription through epigenetic modifications. During energy
deprivation, the eNoSC (energy-dependent nucleolar silencing complex) mediates
silencing of rDNA loci through SIRT1-dependent deacetylation.147 Starvation activates the
lysine demethylase KDM2A, reducing histone H3 methylation to repress rRNA
transcription.148

Cellular proliferation and energy homeostasis are linked to ribosomal synthesis through
bidirectional regulation. Ribosome biogenesis, including rRNA transcription, processing,
and assembly of ribosome subunits, is closely monitored and changes in its efficiency
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result in feedback signals on growth and energy production pathways.145,147 The cellular
mechanisms that sense changes in ribosome synthesis are not well understood, but
appear to converge on at least two central pathways – p53 and mTOR. Inhibition of rRNA
transcription with actinomycin or 5-fluorouracil activates p53 signaling through relieving
inhibition of mdm2.149 In turn, p53 upregulates p21 to induce nucleolar stress, inhibits the
cell cycle, and suppresses mitochondrial energy production.150 The mechanisms
supporting this regulation are not clear but may rely on direct interactions between the
5.8S rRNA and the p53 complex.151 Moreover, activation of p14ARF alone, which also
binds 5.8S rRNA, is sufficient to suppress mature rRNA production.152

Similar activation of p53 has also been documented with knockout of rRNA processing
factors, such as UTP18, Bop1, or Pes1.153,154 In these studies, defects in production of
either 18S or 28S rRNA were sufficient to elicit the p53 response. Additional steps in
ribosome assembly are also monitored by the p53 axis. Numerous ribosomal proteins
bind mdm2, and depletion of some of these ribosome proteins, including rps9 and rpl23,
result in p53-dependent cell cycle inhibition.149,153 The selectivity of this response
indicates that ribosome quality control monitors the presence of specific proteins during
assembly.

mTOR also responds to perturbations in rRNA synthesis. Inhibition of transcription of
rRNA with actinomycin or by silencing subunits of RNA polymerase results in activation
of mTORC1 and phosphorylation of its downstream targets.123 mTORC1-mediated
phosphorylation of S6K and 4EBP1 is also upregulated when rRNA processing is
impaired. Expression of mutant BOP1 or knockdown of PeBoW complex components
78

activates mTOR and stimulates polysome formation and translation elongation.124 These
studies suggest that mTOR is activated in response to perturbed rRNA synthesis as a
compensatory mechanism to support protein synthesis and cell growth. How defects in
ribosome production are monitored and translated to mTOR activity changes is poorly
understood. Components of mTORC1, such as Raptor, have been detected in nucleolar
fractionations, raising the possibility of direct communication with rRNA synthesis
machinery.121,155 Interaction with ribosomal proteins may also mediate the feedback
regulation of ribosome biogenesis on mTOR. mTORC2 docks on cytosolic ribosomes,
promoting its activation by growth factors.122,156 Knockdown of ribosome proteins
attenuates this interaction and reduces polysome formation and translation.122

Our findings linking U17 snoRNAs and mTOR activity provide further evidence of
crosstalk between rRNA biogenesis and central metabolic pathways. In this case,
reducing U17 snoRNA-mediated rRNA processing efficiency results in activation of
mTOR to maintain normal steady-state abundance of mature rRNA. During baseline
conditions, no changes in p53 activity, as measured by expression of p21 or p14ARF
mRNA, were observed in U17 snoRNA-deficient cells. Similar to other groups, we also
observed a shift in the distribution of ribosomal pool toward polysome formation. While
mTOR activation by perturbed rRNA biogenesis is not a novel phenomenon, our work
provides the first demonstration that loss of a snoRNA can initiate this process. Moreover,
this study also the first to show that mTOR activation in this setting extends beyond
translation regulation to also include rewiring of cellular metabolism and resistance to
metabolic stress. Interestingly, though U17 haploinsufficiency interferes with rRNA
processing, cells compensate to produce normal amounts of rRNA and grow at similar
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rates to wild-type cells. However, more complete knockdown of U17 snoRNAs induces
growth arrest and markedly reduced rRNA levels (unpublished observations). This
suggests that the cellular response to deficiencies in rRNA production depends on the
degree of impairment involved. Extending this notion may help interpret the seemingly
divergent observations that rRNA synthesis defects activate both mTOR and p53
response pathways, which have opposing effects on cellular proliferation and energy
production. Mild perturbations in rRNA synthesis, such as those induced by U17
haploinsufficiency or expression of mutated rRNA processing factors (e.g., BOP1), can
be overcome by mTOR activation with the resulting effects on protein synthesis and
energy metabolism. On the other hand, severe reductions in rRNA synthesis, such as
complete U17 snoRNA knockdown or abrogation of rRNA transcription, cannot support
cell growth and the p53 pathway is recruited to halt cell division and induce apoptosis.

U17 snoRNA-mediated regulation of mTOR activity may shed light on other metabolic
phenotypes associated with the Snhg3 locus and U17 snoRNAs. Our group previously
showed that haploinsufficiency of U17 snoRNAs resulted in augmented flux of cholesterol
into mitochondria and decreased ER cholesterol esterification.91 This change in cellular
cholesterol trafficking was associated with remodeling of mitochondria-associated ER
membranes (MAM), with evidence for an important role for HUMMR, an outer
mitochondrial membrane adaptor whose expression is regulated by U17 snoRNAs.
mTOR is an important regulator of intracellular cholesterol trafficking. Lysosomal
cholesterol activates mTORC1, which facilitates distribution of cholesterol to other
organelles including the plasma membrane and mitochondria, resulting in decreased
esterified cholesterol within ER pools. mTORC2 signaling also governs the formation and
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function of MAM.127,157 In this way, increased mTOR activity during U17 snoRNA
haploinsufficiency may drive increases in MAM to provide more contact sites for lipid
transfer from ER to mitochondria.

The link between Snhg3 expression, mTOR activity, and metabolism may also be relevant
in human cancer. Snhg3 is upregulated in numerous cancers, including hepatocellular
carcinoma, colorectal cancer, prostate adenocarcinoma, ovarian cancer, and breast
adenocarcinoma.95,96,158-160 The simplest explanation for these findings is that increased
Snhg3 expression provides additional U17 snoRNAs to meet demand for rRNA synthesis
requirements in cancer. However, a defining feature of many of these neoplasms is the
Warburg effect, or a shift toward anaerobic glycolysis and away from mitochondrial
oxidative metabolism. That Snhg3 overexpression correlates with this glycolytic
phenotype is intriguing in light of our findings in Snhg3 deficient cells, which show
diminished extracellular acidification rates and greater mitochondrial glucose oxidation.
While we have not yet examined the metabolic consequences induced by Snhg3
overexpression, we hypothesize that this perturbation would enhance glycolytic
metabolism. In line with this, the degree of Snhg3 expression correlates strongly with
expression of glycolytic enzymes in ovarian cancer.161 Moreover, in cultured tumor cells,
knockdown of the Snhg3 locus suppressed mRNA expression of glycolytic enzymes and
promoted expression of several TCA enzymes.161 These findings provide evidence that
the Snhg3 locus may be a promising therapeutic target in cancer and demonstrate its
importance in metabolic stress beyond the context of nutrient overload.
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6.4 U17 snoRNAs and metabolic stress in vivo
In this work, we report evidence that U17 snoRNAs regulate hepatic metabolism under
baseline and during metabolic stress. On chow diet, knockdown of U17 snoRNAs with
two distinct LNAs in the liver recapitulates the redox changes observed in 2E4 mutant
cells, with increased NADPH and a reduced GSSG:GSH ratio. Similarly, knockdown of
U17 snoRNAs increases 47S rRNA abundance and augments mTOR expression and
AKT phosphorylation. Similar to Snhg3 mutant cells, knockdown of U17 snoRNAs in the
liver reduced key features of hepatic lipotoxicity. In mice maintained on the MCD diet for
3 weeks, we found that U17 knockdown reduced hepatic steatosis, markers of oxidative
stress, and inflammatory infiltrates. Depletion of U17 snoRNAs also reduced expression
of several mRNAs associated with fibrosis and matrix remodeling. To examine the role of
U17 snoRNAs in the metabolic syndrome, we fed mice a high-fat diet for 4 weeks to
induce obesity and insulin resistance. In this context, treatment with U17 LNAs from diet
onset improved glucose tolerance and insulin-mediated glucose disposal. These findings
demonstrate that targeting U17 snoRNA expression can prevent some adverse metabolic
effects of diet-induced steatohepatitis and obesity.

The link between U17 snoRNAs and mTOR function has important implications for energy
homeostasis in the setting of the metabolic syndrome. The role of mTOR signaling in
diabetes and obesity is currently under intense scrutiny, with its activity associated with
both beneficial and adverse metabolic consequences. In many tissues, active mTOR
signaling is essential for protective responses to nutrient overload. In white adipose
tissue, mTORC1 facilitates lipogenesis, promotes lipid droplet formation, and suppresses
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lipolysis, helping to sequester excess toxic lipids.162 Adipose-specific knockout of Raptor,
a key mTORC1 regulator, results in lipodystrophy and excessive lipid deposition in the
liver and skeletal muscle, leading to insulin resistance.162,163 In pancreatic b-cells,
mTORC1 activity is essential for glucose homeostasis. Inhibition of mTOR signaling with
rapamycin or genetic ablation impairs b-cell proliferation, insulin processing, and glucosestimulated insulin release, leading to severe glucose intolerance.164 Growth and
maintenance of skeletal muscle mass also requires intact mTOR signaling. Skeletal
myocyte-specific knockout of mTOR or Raptor downregulates dystrophin and causes
profound myopathy and premature death.165

Excessive mTOR activity during obesity may exacerbate lipid-induced dysfunction in
other tissues. As in many organs, mTORC1 signaling in the liver promotes mitochondrial
biogenesis, expression of catabolic enzymes, and augments antioxidant capacity.166
However, it also potently stimulates lipogenesis and VLDL production through the
SREBP1 pathway.167 Aberrant activation of the mTORC1 axis in the liver during high-fat
diet feeding exacerbates hyperlipidemia and accelerates hepatic steatosis and
inflammation.168 In this context, mTORC1 also drives activation of stellate cells to promote
fibrosis.169 However, mTORC2 appears to play a distinct role from mTORC1 in hepatic
metabolism. Hepatocyte-specific deletion of Rictor, a key component of mTORC2, blunts
glucose uptake, suppresses glycolysis, and induces hepatic insulin resistance.170,171
Abrogation of mTORC2 in the liver promotes constitutive gluconeogenesis and
hyperglycemia, whereas augmenting mTORC2 signaling ameliorates insulin resistance
in response to high-fat diet.171
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Aberrant mTORC1 activity in many immune cells underlies sequelae of the systemic
inflammation observed in obesity.172 mTORC1 signaling promotes inflammatory cytokine
release in cultured macrophages in response to lipid overload, in part through mediation
of TLR signaling.109,110 Conversely, mTOR inhibition blunts release of IL-1 and abrogates
lipotoxicity in these cells.110 In vivo, macrophage-specific knockout of mTOR dramatically
reduces adipose inflammation and blunts steatohepatitis during high-fat feeding through
blockade of M2 polarization.173,174

Given the opposing roles of mTOR and nutrient utilization in important metabolic tissues,
the effects of U17 snoRNA expression in the setting of obesity and diabetes are not
straightforward and may be highly dependent on the tissue in question. Depletion of U17
snoRNAs and the resulting increase in mTOR activity in adipose tissue may enhance
lipogenesis and reduce lipolysis, leading to reduced lipid deposition in the liver and
skeletal muscle. In b-cells, U17 snoRNA deficiency may promote glucose uptake and
oxidative metabolism, leading to enhanced insulin secretion and improved glucose
tolerance. Hepatic U17 snoRNA depletion may alter liver metabolism in many ways.
Upregulated mTORC1 activity will involve a balance between increased oxidative
capacity and stimulation of lipogenesis in response to lipid overload. The resulting
augmented antioxidant capacity within hepatocytes may reduce oxidative stress and
suppress inflammation and stellate cell activation. Hepatic glucose production may be
diminished through activation of mTORC2, with subsequent improvements in glucose
tolerance. U17 snoRNA knockdown in skeletal muscle could also lead to enhanced insulin
sensitivity through mTORC2/AKT signaling and b-oxidation capacity. Ultimately, the role
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of U17 snoRNAs in the metabolic syndrome will also hinge on the overall contribution of
these tissues to the global picture of metabolic dysregulation.

The role of U17 snoRNAs in human disease has not been explored. In mice, MCD diet or
high-fat feeding induces expression of the Snhg3 locus in the liver. It is not known whether
Snhg3 is induced in NAFLD or whether this locus responds to metabolic stress in other
tissues. There are also currently no known diseases that are associated with
polymorphisms in Snhg3; however, relatively little effort has been invested in identifying
mutations in noncoding loci. There might also be polymorphisms outside of the Snhg3
locus that regulate its expression. The studies herein suggest that genetic alterations that
impair Snhg3 expression could suppress metabolic derangements like insulin resistance
and hepatic steatosis in obese individuals. Conversely, polymorphisms that augment
Snhg3 expression may exacerbate these conditions. This hypothesis may be relevant for
“metabolically healthy” obesity, in which obese individuals do not develop hyperlipidemia
or diabetes or in populations that are predisposed to developing diet-induced diabetes
and hyperlipidemia, such as Native Americans and Hispanics.

6.5 Future directions and outstanding questions
Our work describes an important role for U17 snoRNAs in metabolic stress in cultured
cells and in vivo. We have discovered that this role encompasses metabolic rewiring and
increased mTOR activity. Nonetheless, the mechanistic details underlying this function
and how U17 snoRNAs modulate metabolism in organ systems beyond the liver will
require future studies. Moreover, our understanding of U17 snoRNA function in vivo is
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based on pharmacological knockdown, in which U17 depletion occurs in multiple tissues
and to varying extents. Generation of U17 snoRNA knockout animals, with tissue-specific
deletion in metabolic organs like the liver, skeletal muscle, and adipose depots, will
greatly improve our understanding of the physiological role of these snoRNAs. Given that
U17 snoRNAs are critical for rRNA production, constitutive knockout of the Snhg3 locus
may impair organogenesis or result in nonviable embryos. Inducible knockout models will
allow manipulation of U17 snoRNA expression at different stages in the progression of
diet-induced obesity and diabetes.

There are also a number of unanswered questions regarding the evolution of the Snhg3
locus. In yeast, the U17/snR30 snoRNA is independently encoded within its own gene
and is constitutively expressed. During the course of eukaryotic evolution, two important
changes occurred in the structure of this locus. First, the sequences encoding the U17
snoRNA became incorporated within intronic regions of a noncoding RNA gene, allowing
additional levels of control for transcriptional and post-transcriptional regulation, as both
synthesis and splicing of the nascent host gene transcript are required to produce U17
snoRNAs. This organization, with snoRNAs occupying intronic regions of coding or
noncoding genes, is a common feature among snoRNA loci. In some cases, the host
gene and the snoRNAs encoded within serve a common purpose. For example, the
Rpl13a locus encodes a component of the large ribosomal subunit and also produces
snoRNAs that modify rRNA. The precise function of the SNHG3 lncRNA is not known but
our studies indicate its expression does not affect lipotoxicity or oxidative stress.
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The Snhg3 locus encodes U17A and U17B, which share 94% sequence identity. The
presence of these two snoRNAs may have resulted from a simple duplication event during
evolution, with the divergence in sequence bearing no functional consequence and
accounted for by genetic drift. However, if no selective pressure existed to maintain both
copies of U17 snoRNAs, then we might expect a much larger sequence variation or the
loss of one copy altogether, as occurs with a number of pseudogenes. On the other hand,
the presence of both U17 snoRNAs could be beneficial: by increasing the gene dosage,
two copies of U17 snoRNAs may provide “biological insurance” for rRNA production in
the event one copy is mutated or lost. This would imply that U17A and U17B are
functionally redundant, as has been suggested by previous work from our group.91 It may
also be possible that U17A and U17B serve different functions. For example, U17A may
mediate rRNA processing while U17B engages in metabolic regulation, or vice versa.
These possibilities could be addressed by knocking in copies of the Snhg3 locus with
alternate intron deletions.

The finding that U17 snoRNA depletion upregulates mTOR activity and expression
without changing mRNA transcript levels raises the possibility that U17 snoRNAs
modulate specific translation programs. This could occur through numerous mechanisms,
including regulation of bulk translation activity, changes in ribosome structure and
composition, or through alterations in post-transcriptional modification of specific mRNAs.
These hypotheses could be tested using a combination of ribosome profiling and
proteomic approaches. Based on our data so far, we would predict that ribosome
occupancy on transcripts involved in nutrient metabolism or oxidative stress would be
altered by changes in U17 snoRNA expression, either under resting conditions or during
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metabolic stress. Combining these studies with cellular proteomic analyses would
validate ribosome profiling targets and also provide information on proteins that are
altered post-translationally in the setting of U17 snoRNA deficiency. Such experiments
could be performed in vivo in several principal metabolic tissues to identify whether and
how U17 snoRNA-mediated translational regulation responds to nutrient and hormonal
cues.

U17 snoRNAs may also mediate translation in ways beyond ribosome biogenesis or
through mTOR signaling. U17 snoRNAs belong to the box H/ACA class of snoRNAs,
which mediate site-specific pseudouridylation within other noncoding RNAs. However,
unlike

prototypical

box

H/ACA

members,

U17

snoRNAs

target

no

known

pseudouridylation sites within typical substrates like rRNA and tRNA. The discovery of
pseudouridine sites within mRNAs and other noncanonical substrates raises the
possibility that these “orphan” snoRNAs may have novel functional capacities.84 U17
snoRNAs associate with dyskerin, a pseudouridine synthase, but whether U17 snoRNAs
can mediate pseudouridylation is completely unknown. New techniques, such as
pseudouridine RNA sequencing, could be used to determine whether U17 snoRNA
deficiency produces alterations in the global pseudouridylation profile. This approach, in
parallel with ribosome profiling and proteomics, will provide a wealth of information on the
role of U17 snoRNAs in post-transcriptional and translational regulation.
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Chapter 7:
Materials and Methods
Animals
All experimental procedures were approved by the Washington University Animal
Studies Committees and were conducted in accordance with the U.S. Department of
Agriculture Animal Welfare Act and the Public Health Service Policy for the Humane
Care and Use of Laboratory Animals.
Chow diet study
Male C57BL/6J mice were obtained from the Jackson Laboratory. Mice were housed with
a 12h:12h light:dark cycle and fed standard chow (LabDiet 5053) ad libitum. For in vivo
knockdown experiments, LNAs (Qiagen) targeting snoRNA U17 or GFP (control) were
injected intraperitoneally into 8-week-old mice at a dose of 3 mg/kg every other day for 3
injections (see Table 1 for LNA sequences). Animals were euthanized 2 days after the
final injection for tissue analyses.
Methionine-choline deficient (MCD) diet study
7-week-old C57BL/6J male mice and 9-week-old female mice were injected
intraperitoneally with U17 or GFP LNAs at a dose of 3 mg/kg every other day for 3
injections and once weekly thereafter for 3 weeks. Following the first week of LNA
treatment, animals were placed on MCD diet (MP Biomedicals 02960439) or matched
control diet (MP Biomedicals 20960441) for 3 weeks. Animals were euthanized one week
after the final LNA injection for tissue collection and analyses. Liver specimens were fixed
in neutral buffered formalin (Sigma HT501640) and submitted to the Advanced Imaging
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and Tissue Analysis Core of the Digestive Diseases Research Center at Washington
University for sectioning and immunohistochemistry.
High fat diet (HFD) study
6-week-old C57BL/6J male mice were obtained from the Jackson Laboratory and
maintained on 60% fat diet (Research Diets D12492) or 10% fat diet (Research Diets
D12450B) for 4 weeks. At the start of the diet period, animals on high-fat diet were injected
intraperitoneally with U17 snoRNA or control LNAs at a dose of 3 mg/kg every other day
for 3 injections and once weekly thereafter for the duration of the study. Metabolic
analyses (glucose and insulin tolerance tests) were performed after 4 weeks of low-fat or
high-fat feeding. Animals were euthanized 3 days after metabolic testing for tissue
collection and analyses.
Intraperitoneal glucose and insulin tolerance tests
In vivo dynamic testing was carried out after a 4-hour fast according to guidelines of the
NIH-sponsored

National

Mouse

Metabolic

Phenotyping

Centers

(http://www.mmpc.org/shared/protocols.aspx). Mice were injected intraperitoneally with 1
g/kg glucose (GTT) or 0.75 U/kg insulin (ITT). Blood glucose was measured at 0, 15, 30,
60, and 120 minutes following injections using a glucometer (Contour). For GTT studies,
plasma was analyzed for insulin content at 0 and 15 minutes using an ultra-high sensitivity
ELISA immunoassay (Crystal Chem).
Cell culture
CHO K1 cells (ATCC CCL-61) and CHO-derived cell lines were cultured in a 1:1 mixture
of Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma D6429) and Ham’s F-12 nutrient
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medium (Sigma N6658) supplemented with 5% fetal bovine serum (Sigma F2442), 2 mM
L-glutamine, and 1 mM sodium pyruvate. NIH 3T3 cells (ATCC CRL-1658) were
maintained in DMEM with 10% fetal calf serum (Sigma 12133C) and 2 mM glutamine.
For lipotoxicity experiments, growth medium was supplemented with 500 μM palmitate
(Nu-Chek Prep) complexed to BSA (Sigma A8806) at a 2:1 molar ratio, as described
previously41. Normal human skin fibroblasts (NSF, ATCC CRL-1474) were grown in
DMEM supplemented with 10% inactivated fetal bovine serum.
Genetic screen
The loss of function genetic screen in CHO-K1 cells to isolate lipotoxicity-resistant
mutants was described previously74. Genes disrupted at the site of retroviral insertion
were identified by 5′ RACE using an oligonucleotide tag and ROSAβgeo sequences. 5′
RACE products were TA-cloned, sequenced, and analyzed by NCBI BLAST.
In vitro Snhg3 knockdown
Locked nucleic acid oligonucleotides (LNAs, Qiagen) were designed to target snoRNA
U17 and SNHG3 lncRNA, or GFP as a control. pGFP-C-shLENTI lentiviral shRNA
constructs (Origene TR30023) were designed to target hamster SNHG3 lncRNA or GFP
as a control. See Table 1 for LNA and shRNA sequences. For LNA knockdown
experiments in NIH 3T3 cells, 4.0 x 104 cells were seeded per well in a 6-well dish and
transfected the following day with 25 nM LNA using Lipofectamine 3000 (ThermoFisher
L3000015). SNHG3 and U17 expression and palmitate-induced cell death were analyzed
48 h following transfection. For LNA knockdown in CHO cells, 2.5 x 105 cells were plated
in 6 cm dishes and transfected the next day with 25 nM LNA using Lipofectamine 3000.
For LNA knockdown in primary human fibroblasts, 5.0 x 104 cells were plated in 6 well
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plates, or 1.5 x 105 cells were seeded in 6 cm dishes. Cells were transfected with 25 nM
LNA the following day using Lipofectamine 3000. For shRNA transduction experiments,
virus was harvested from HEK293T cells (ATCC CRL-3216) that were transfected using
Lipofectamine 3000 with shRNA constructs and Mission helper plasmids (Sigma
SHP001). 5.0 x 105 CHO cells were seeded in 6 cm dishes, grown for 24 h, and
transduced with shSCR or shSNHG3 lentiviral particles. After expansion of the
population, the top 20 percent of cells were flow sorted and maintained as the transduced
population.
Cell death assays
Cell death was quantified by flow cytometric analysis (104 cells/sample) of annexin VEGFP (BioVision 1004) and propidium iodide (ThermoFisher 1304MP) staining. Annexin
V-EGFP and/or propidium iodide positive cells were considered dead.
Detection of ROS
Following indicated treatments, cells were rinsed with PBS and incubated in PBS
containing 0.5 mM MgCl2, 0.92 mM CaCl2 and 3 μM CM-H2DCFDA (ThermoFisher
C6827) for 1 h at 37 °C or 2.5 μM MitoSox Red (ThermoFisher M36008) for 20 minutes
at 37 °C. Cells were trypsinized and mean fluorescence was determined by flow
cytometric analysis of 104 cells/sample.
Live cell imaging
CHO and 2E4 cells were transduced with retroviral particles containing plasmids
encoding roGFP1 tagged with a mitochondrial localization sequence175. 1 x 105 cells were
seeded in 35 mm glass bottom culture dishes and visualized using a Zeiss LSM 880
Airyscan microscope.
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Cellular respiration assays
Oxygen consumption rates (OCR) were measured using a Seahorse XF24 analyzer
(Agilent). 4.0 x 104 cells were seeded per well in Seahorse culture plates (Agilent 100850)
and incubated overnight in growth medium. Cells were incubated in XF base medium
(Agilent 102353) for 1 h at 37 °C in a CO2-free incubator. OCR was determined after
injection of 5 mM glucose or 2 mM glutamine and following serial additions 1 µM
oligomycin (Sigma 75351), 2 µM fluorocarbonyl cyanide phenylhydrazone (FCCP, Sigma
C2920), and 2 µM antimycin A (Sigma A8674). After the assay, cells were rinsed with
PBS, trypsinized, and quantified by trypan blue staining. For experiments measuring OCR
with mTOR inhibitors, 2.0 x 104 cells were seeded per well in Seahorse culture plates.
The following day, cells were treated with DMSO, rapamycin (50 nM, Sigma R0395), or
torin 1 (250 nM, Tocris 4247) for 24 h prior to measurement of OCR as described above.
Measurement of NAD(H) and NADP(H)
Nicotinamide adenine nucleotides were quantified in CHO and 2E4 cells (1 x 106 cells)
and liver tissue (10 mg) using an NAD+/NADH Assay Kit (Abcam ab65348) and an
NADP/NADPH Assay Kit (Abcam ab65349) according to manufacturer instructions.
LC-MS metabolite analysis
1 x 106 CHO and 2E4 cells were seeded in 6 cm dishes and incubated overnight in growth
medium. Cells were rinsed in PBS and incubated in growth medium (DMEM-low glucose
(Sigma D6046), 5% FBS, 2 mM glutamine) containing 15 mM [U-13C]glucose (Cambridge
Isotope Laboratories CLM-1396) for 6 h. Polar metabolites were extracted from cellular
and culture medium samples with 80% methanol in water (v/v). Samples were analyzed
on a Dionex UltiMate 3000 UHPLC coupled to a Thermo Scientific Q Exactive Plus
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Orbitrap. 3 µL of the reconstituted cell extracts and 2 µL of media samples (1:100 and
1:1000 dilution) were injected onto a SeQuant ZIC-pHILIC column (2.1 x 100 mm, 5 µm)
at 40 °C. Mobile phase A was 95% water, 5% acetonitrile (v/v) with 20 mM ammonium
bicarbonate, 0.1% ammonium hydroxide and 4 µM medronic acid. Mobile phase B was
95% acetonitrile, 5% water (v/v). The flow rate was set to 0.25 mL/min and the following
gradient was applied: 0-1 min, 90% B; 1-14 min, 90%-25% B; 14-15.5 min, 25% B; 15.518 min, 25%-90% B; 18-31 min, 90% B. From 19.5-27.5 min, the flow rate was increased
to 0.4 mL/min for faster equilibration. Electrospray ionization (ESI) was used in negative
polarity with 2.8 kV spray voltage. High-resolution mass spectrometry data were acquired
in full scan mode from 65-900 m/z with 140,000 resolution and an automatic gain control
(AGC) target of 1e6. The data were analyzed using Skyline 4.2176 and natural isotope
abundance correction was performed with AccuCor177.
Glutathione quantification
GSH and GSSG were extracted from 1 x 106 cells or 5 mg liver tissue with 50% acetonitrile
in water (v/v) spiked with 500 ng internal standards (GSH-d5 (Santa Cruz sc-489493) and
13

C15N-GSSG (Toronto Research Chemicals G597972) and derivatized with 310 mM N-

methylmaleimide178. Samples were analyzed using a 20AD Shimadzu HPLC system
coupled to an Applied Biosystems API 4000 tandem mass spectrometer. Samples (3 µL)
were injected onto a ThermoFisher Hypercarb column (3 µm, 150 mm x 3 mm). Mobile
phase A was 1% formic acid in water and mobile phase B was 1% formic acid in 1:1
acetonitrile:methanol (v/v). The HPLC gradient was started at 30% of solvent B and 70%
of solvent A and increased to 100% of B in 4 min, which was held for 2 min. The MS
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analysis was conducted in positive ion electrospray ionization with multiple reaction
monitoring (MRM). Precursor and product ions are shown below.
Precursor and product ions for glutathione quantification by LC-MS/MS
MRM Ions

Precursor Ion (Q1)

Product ion (Q3)

GSH-NEM

433.3

304.4

GSH-d5-NEM

438.3

304.4

GSSG

613.4

355.2

GSSG-13C215N4

619.4

361.2

Oxysterol quantification
Liver tissues were homogenized in PBS buffer (4x volume of tissue wet weights) using
an Omni Bead Ruptor homogenizer (Omni International, Inc). Oxysterols (3β, 5α, 6βtriohydroxycholestane (C-triol) and 7-keto-cholesterol) were extracted with 200 µL of
methanol from 50 µL of the homogenate. Deuterated oxysterol compounds (7-ketocholesterol-d7 and triol-d7, 10 ng each) were used as internal standards and were added
to the samples before extraction. The calibration standards of these two oxysterols
containing their deuterated internal standards were also prepared for the absolute
quantification of the oxysterols in liver tissues. Oxysterols and their standards were
derivatized with N, N-dimethylglycine (DMG) to increase MS sensitivity. Sample analysis
was performed with a Shimadzu 20AD HPLC system, a Shimadzu autosampler coupled
to a triple quadrupole mass spectrometer (API 46500+Qtrap: Applied Biosystems)
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operated in MRM mode. The positive ion ESI mode was used for detection of derivatized
oxysterols. An Agilent C18 HPLC column (Eclipse XDB-C18 3.0 x 100mm, 3.5 µm) was
used with mobile phases (A: 1 % formic acid in water, B: 1% formic acid in 1:1
acetonitrile/methanol). The study samples were injected in duplicate for data averaging.
Data processing was conducted with Analyst 1.6.3 (Applied Biosystems).
Triglyceride quantification
1 x 106 CHO and 2E4 cells were seeded in 6 cm dishes and incubated overnight in growth
medium. Cells were treated for 16 h with 500 µM PALM or control BSA medium, as
described above. After rinsing with PBS, cells were harvested and lysed in 5% NP-40.
Lysates were incubated at 85 °C for 3 minutes to solubilize triglycerides. Samples were
treated with lipase and total glycerol quantified using a Triglyceride Assay Kit (Abcam
ab65336).
Liver transaminase quantification
Plasma was prepared from 300 µL of whole blood collected from animals by IVC
puncture. Activity of alanine transaminase (ALT) and aspartate aminotransferase (AST)
in 10 µL of neat plasma was determined using ALT (Teco diagnostics, NC9851323) and
AST (Teco diagnostics, NC9851324) quantification kits according to manufacturer
guidelines.
Fatty acid uptake
Fluorescent fatty acid uptake was performed as previously described (Richards et al.,
2001). 1 x 106 CHO and 2E4 cells were seeded in 6 cm dishes. The following day, cells
were trypsinized and counted by trypan blue staining. 2 x 106 cells were incubated at 37
°C for 1 min in fatty acid uptake solution (20 μM fatty acid-free BSA and 6 μM BODIPY96

3821 (ThermoFisher D3821). Cells were washed with ice cold PBS, pelleted,
resuspended in growth medium. Mean BODIPY fluorescence was determined by flow
cytometry (104 cells/sample).
14

C-palmitate oxidation

Palmitate oxidation rates were determined by

14

CO2 capture as described previously179.

5 x 105 CHO and 2E4 cells were seeded in T25 flasks. The next day, cells were incubated
in growth medium spiked with 0.2 µCi/ml [1-14C]palmitate (Perkin-Elmer EC075H250UC)
and flasks were sealed with rubber septa pierced by a center well device carrying
Whatman chromatography paper. After 6 h, cells were quenched in 70% perchloric acid
and

14

CO2 was captured by adding 2 M NaOH to the chromatography paper. After 30

minutes, the chromatography paper was removed from flasks, placed in scintillation fluid,
and incubated overnight at room temperature.

14

CO2 was quantified by scintillation

counting and normalized to cellular protein.
mTOR signaling
To assess mTOR activity in WT and 2E4 cells, 2.5 x 105 cells were seeded in 6 cm dishes.
The following day, cells were rinsed in PBS and incubated either in complete or serumfree culture medium overnight (16 h). Serum-starved cells were then treated with or
without 250 nM insulin for 30 minutes prior to cell lysis and immunoblot analyses. To
measure mTOR activity in WT and 2E4 cells during oxidative stress, 2.5 x 105 cells were
seeded in 6 cm dishes. The following day, cells were treated with 1 mM H2O2 for 16 h. To
assess mTOR activity in human skin fibroblasts in the setting of U17 snoRNA knockdown,
1.5 x 105 cells were seeded in 6 cm plates. The following day, cells were transfected with
25 nM LNA targeting GFP (control) or U17 snoRNAs for 24 h. Cells were then rinsed
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twice with PBS and incubated 16 h in serum-free culture medium. The next day, serumstarved cells were treated with 100 nM insulin for 30 minutes prior to cell lysis. For inhibit
ion of mTOR signaling, cells were treated with rapamycin (50 nM) or torin 1 (250 nM) as
described in Figure Legends. To measure mTOR activity in tissues following euthanasia,
livers were rapidly excised and homogenized.
Immunoblotting analyses
Cell lysates and tissue homogenates were prepared using RIPA buffer (50 mM Tris-Cl,
150 mM NaCl, 0.5% Nonidet P-40, 0.1% SDS) supplemented with 1X Protease Complete
(Roche 11697498001) and Phosphatase Inhibitor Mini Tablets (ThermoFisher A32957).
Proteins (20 μg) were separated by 4-12% Bis-Tris polyacrylamide gel electrophoresis
and transferred to PVDF membranes using an iBLOT 2 system (ThermoFisher). Blots
were blocked in 5% non-fat milk for 1 h at room temperature and probed overnight with
antibodies against phospho-Akt (Cell Signaling 4060), Akt (Cell Signaling 4691), mTOR
(Cell Signaling 2983), phospho-4E-BP1 (Cell Signaling 2855), 4E-BP1 (Cell Signaling
9452), phospho-S6K (Cell Signaling 9234), S6K (Cell Signaling 2708), and GAPDH
(Fisher AB2302MI). Appropriate secondary antibodies conjugated to horseradish
peroxidase were used to visualize proteins in combination with HRP substrate.
Ribosome analyses
1 x 106 CHO and 2E4 cells were seeded in 10 cm dishes and incubated in growth medium
for 24 h. Cells were treated with 10 µg/ml cycloheximide for 5 minutes, then trypsinized
and counted using trypan blue staining. 15 x 106 cells were lysed in polysome lysis buffer
(20 mM Tris pH 7.2, 130 mM KCl, 10 mM MgCl2, 2.5 mM DTT, 0.5% NP-40, 0.2 mg/ml
heparin) and loaded onto 7-47% sucrose gradients. Samples were centrifuged 36,000
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rpm for 3 h at 4 °C using a Beckman SW-41 rotor and Beckman L8-80M centrifuge.
Gradients were fractionated using a Brandel Gradient Fractionator system with
continuous monitoring of sample absorbance at 254 nm to generate polysome profiles.
To assess liver ribosomes, 10-week-old ad libitum-fed male mice treated with GFP or U17
LNAs for 1 week (3 injections) were injected with 100 µl of cycloheximide (20 mg/ml) in
PBS by tail vein180. After 5 minutes, animals were sacrificed by cervical dislocation and
livers were excised and snap-frozen in liquid nitrogen. To prepare polysome profiles, ~100
µg liver tissue was homogenized in polysome lysis buffer using a Dounce homogenizer
(glass-glass). RNA content in lysates was determined and 60 µg RNA was loaded onto
sucrose gradients and processed as above.
Measurement of newly synthesized rRNA
rRNA synthesis was assessed by Click-it Nascent RNA Capture kit (ThermoFisher
C10365). Cells were incubated with 0.4 mM 5-ethynyl uridine (5-EU) in growth medium
for 30 min and total RNA was collected with TRIzol. Cells were washed twice with PBS
and chased in normal growth medium for indicated time points. 5-EU-labeled rRNAs were
chemically clicked to biotin and captured by streptavidin T1 beads. Isolated RNAs were
purified and quantified by RT-qPCR.
Statistics
Results are expressed as mean ± SEM for a minimum of 3 independent experiments. For
directed comparisons, the statistical significance of differences in mean values was
determined by a two-tailed or paired Student’s t test using GraphPad Prism 8 for Mac OS
X (version 8.0a) as indicated. p < 0.05 was considered significant.
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Table 1. Oligonucleotide sequences.
Application
shRNA

Target

Oligo Sequence

shSNHG3

CAAGCACTTGTTCATAGCGGTTCTGAGTC

U17 LNA
1

+A*+A*+G*+T*+C*G*T*A*G*G*A*A*T*A*T*+G*+C*+A*+G*+G

in vitro and
in vivo LNA

U17 LNA
2

+G*+A*+C*+T*+C*T*G*A*G*A*A*G*T*C*G*+T*+A*+G*+G*+A

knockdown

SNHG3
LNA

+T*+T*+G*+A*+C*C*G*G*G*T*C*A*A*G*A*+A*+C*+A*+A*+G

GFP LNA

+T*+C*+A*+C*+C*T*T*C*A*C*C*C*T*C*T*+C*+C*+A*+C*+T

Cg U17
forward

GCGCCTGTATATTCCTACAGC

Mm U17
forward

AACGGGAGCTTAGGGCATT

36B4
forward

ATCCCTGACGCACCGCCGTGA

36B4
reverse

TGCATCTGCTTGGAGCCCACGTT

U17
SLRT1

GCGTGGTCCCGACCACCACAGCCGCCACGACCACGCTTTT
GT

SLRT1
reverse

TCCCGACCACCACAGCC

Mm
SNHG3
forward

TCTCTCTAGGCGTCGCTCTC

Mm
SNHG3
reverse

CTAATGGCCGAGGCTGTAAC

Cg
SNHG3
forward

AAGAAGTCGCATCGGTACTGC

RT-qPCR
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Cg
SNHG3
reverse

GGTGCAAGTCCCCAAAGTTA

Cg 18S
forward

AAGTGGCGTTCAGCCACCCG

Cg 18S
reverse

CCAGTCAGTGTAGCGCGCGT

Cg/Mm
28S
forward

TCTCGCTGGCCCTTGAAAAT

Cg/Mm
28S
reverse

ACCTACATTGTTCCAACATGCC

Cg 45/47S
forward

GGTCGGTGATATGGGGGAAC

Cg 45/47S
reverse

TGCGTTCGAAGTGTCGATGA

Mm 18S
forward

GGCCTGCGGCTTAATTTGAC

Mm 18S
reverse

CGGAATTAACCAGACAAATCGC

Mm 47S
forward

CACGCTGTCCTTTCCCTATTA

Mm 47S
reverse

CGACAGACCCAAGCCAGTAAA

Cg CS
forward

AGGTGCTGGAGTTATGGCTTG

Cg CS
reverse

GGCCTGCTCCTTGGGTATC

Cg IDH2
forward

GACCTCGCGTGTTCGGGA

Cg IDH2
reverse

CGAGTCATCTCATCGCCGT
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Cg MDH2
forward

GAGGTCGTTGGAGTCACTTGT

Cg MDH2
reverse

TATCGTAGAGGGTCAGGCGG

Cg SDHA
forward

CGAACAGGCCACTCACTCTT

Cg SDHA
reverse

GAAGTAGGTCCGCCCATAGC

Cg OGDH
forward

TGCCTACCAGAGTCCCCTTT

Cg OGDH
reverse

GCTACATGGTGCCCTCGTAT

Cg CD36
forward

TGCTGGCAACAAACCACAAA

Cg CD36
reverse

CTCAGTGGAAGAGCCCTAGC

Cg CPT1a
forward

GAGGGCAGCCATACTCATCC

Cg CPT1a
reverse

ACATCTGGACTCCCCCTCTT

Cg
PPARA
forward

ACTTACTGGCTTCTTCCCTTCC

Cg
PPARA
reverse

TGTGTCATTATTTGGGAGCTGG

Cg HADH
forward

ATGGATGCTCTGTCCCTCCG

Cg HADH
reverse

GAGACCAACACAGCAGACCC

Cg
ACADL
forward

TGCATGTTTCTTTAAGGTGTTCTC

102

Cg
ACADL
reverse

TTGCCAGCTTTCTCCCACAA

Mm
COL1A1
forward

AGCACGTCTGGTTTGGAGAG

Mm
COL1A1
reverse

GACATTAGGCGCAGGAAGGT

Mm
COL2A1
forward

GTAACTTCGTGCCTAGCAACA

Mm
COL2A1
reverse

CCTTTGTCAGAATACTGAGCAGC

Mm
COL3A1
forward

CTGTAACATGGAAACTGGGGAAA

Mm
COL3A1
reverse

CCATAGCTGAACTGAAAACCACC

Mm EMR1
(F4/80)
forward

TGACTCACCTTGTGGTCCTAA

Mm EMR1
(F4/80)
reverse

CTTCCCAGAATCCAGTCTTTCC

Mm IL1B
forward

GCAACTGTTCCTGAACTCAAC T

Mm IL1B
reverse

ATCTTTTGGGGTCCGTCAACT

Mm CCR2
forward

ATCCACGGCATACTATCAACATC

103

Mm CCR2
reverse

CAAGGCTCACCATCATCGTAG

Mm
TIMP1
forward

GCAACTCGGACCTGGTCATAA

Mm
TIMP1
reverse

CGGCCCGTGATGAGAAACT

Cg, cricetulus griseus; Mm, mus musculus; *, phosphorothioate linkage; +, LNA base
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